Skin care composition comprising vitamin E and vitamin B3

Through the combination of vitamin E, oxiine and nicotinamide, the problem of difficulty in reducing ROS and UV damage in the prior art is solved, and stronger antioxidant and skin barrier functions are achieved to meet consumers' simple and efficient skin care. demand.

CN118973546APending Publication Date: 2024-11-15COLGATE PALMOLIVE CO
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202380031743.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-13
Filing Date
2023-03-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing skin care products are difficult to effectively reduce cell damage caused by reactive oxygen species (ROS) and UV rays, and the complexity of multi-component products is difficult to meet consumers' simple but efficient skin health needs.

Method used

Using the combination of vitamin E (such as α-tocopherol), histidine thiourea derivatives (such as methylthioneine) and vitamin B3 (such as nicotinamide) and pyrrolidone carboxylic acid, the combination of different ratios and amounts can enhance the anti-antibody Oxidation capacity, reduces ROS production and improves skin barrier function.

Benefits of technology

Significantly reduces ROS production, enhances the skin's antioxidant ability, improves skin barrier function, and provides unexpected protective effects beyond the effects of individual compounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005066558780000041
    Figure BDA0005066558780000041
  • Figure BDA0005066558780000051
    Figure BDA0005066558780000051
  • Figure BDA0005066558780000141
    Figure BDA0005066558780000141
Patent Text Reader

Abstract

Disclosed herein are skin care compositions comprising vitamin E (e.g., alpha-tocopherol), a thiourea derivative of histidine (e.g., trithioine), a vitamin B3 compound (e.g., nicotinamide), and / or a pyrrolidone carboxylic acid and / or a salt thereof (e.g., PCA sodium), and methods of using these compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 432,358 filed on December 13, 2022, U.S. Provisional Application No. 63 / 432,356 filed on December 13, 2022, and U.S. Provisional Application No. 63 / 328,857 filed on April 8, 2022, the contents of which are incorporated herein in their entirety for all purposes. Background Art

[0003] Reactive oxygen species (ROS) are free radicals that can react with various cellular proteins in the skin (e.g., collagen, elastin, and glycosaminoglycans). ROS cause cross-linking of collagen and elastin, leading to wrinkles and reducing the skin's self-repair ability. Therefore, skin damage caused by ROS may lead to physiological aging or cause skin diseases. Antioxidants can scavenge and reduce the excess ROS produced and mitigate its damage to cells of different tissues, including the skin.

[0004] Additionally, in the skin health space, recent consumer trends are demanding products that are as simple as possible, yet still provide acceptable skin health benefits that consumers have become accustomed to with products that have multiple ingredients. However, when using fewer ingredients, there is a greater emphasis on maximizing the results and efficacy of each ingredient in order to provide antioxidant and skin health benefits to the consumer.

[0005] Therefore, there is a need for skin health products that are simple but can also provide or exceed the skin health benefits seen in products containing multiple ingredients claiming to have skin health benefits. Summary of the invention

[0006] In one aspect, the inventors have unexpectedly discovered that skin care compositions comprising a combination of vitamin E (e.g., alpha-tocopherol) and a thiourea derivative of histidine (e.g., malthioneine) can be combined with vitamin B3 (e.g., niacinamide) and / or sodium pyrrolidonecarboxylate in various ratios and amounts to provide unexpectedly enhanced reduction and inhibition of cellular damage caused by or associated with free radicals (ROS) and environmental damage (induced by UV rays).

[0007] In one aspect, the skin care composition comprises pyrrolidone carboxylic acid ("PCA") and / or its salt (e.g., sodium PCA), which is believed to be a hygroscopic substance that readily absorbs moisture from the air and can provide hydration to help retain moisture in the skin. In this aspect, without being bound by theory, although pyrrolidone carboxylic acid and its salts are believed not to act as antioxidants when incorporated alone, when combined with alpha-tocopherol and erthionein in the skin care compositions of the present disclosure, it is believed that the skin care composition unexpectedly enhances the ability to reduce ROS production. Unexpectedly, certain skin care compositions of the present disclosure achieve a greater reduction / reduction in ROS production than the cumulative reduction in ROS production that would be expected based on the reduction in ROS production of each compound evaluated individually. ROS measurement in this aspect includes the detection and measurement of free radicals in biological systems.

[0008] In yet another aspect, niacinamide / vitamin B3 can act alone to improve the barrier function of the skin. However, the combination of niacinamide / vitamin B3 with alpha-tocopherol and ergothioneine is believed to unexpectedly enhance the ability to act as an antioxidant due to a greater reduction in ROS production than the reduction observed with each of the compounds alone. ROS measurements include the detection and measurement of free radicals in biological systems.

[0009] Additional areas of applicability of the present disclosure will become apparent from the detailed description provided below. In some aspects, the formulations of the present disclosure can be used in methods for: restoring skin cell vitality, enhancing cellular energy in skin cells (e.g., dermal cells), reducing or inhibiting cell damage associated with reactive oxygen species and / or UV light, and detoxifying skin cells.

[0010] It should be understood that the detailed description and specific examples, while indicating some typical aspects of the disclosure, are intended for purposes of illustration only and are not intended to limit the scope of the disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 is a bar graph depicting the number of thymine dimer positive cells after application of a non-limiting exemplary composition and exposure to UV according to one aspect of the present invention.

[0012] Figure 2A and Figure 2B is a bar graph depicting collagen production after application of a non-limiting exemplary composition and exposure to UV according to one aspect of the present invention.

[0013] Figure 3is a bar graph depicting loricrin production after application of a non-limiting exemplary composition and exposure to UV according to one aspect of the present invention. DETAILED DESCRIPTION

[0014] The following description of various exemplary aspects is merely exemplary in nature and is in no way intended to limit the present disclosure, its application, or uses.

[0015] As used throughout, ranges are used as a shorthand way of describing each and every value that is within the range. Any value within a range can be selected as the endpoint of the range.

[0016] Unless otherwise stated, all percentages and amounts expressed herein and elsewhere in the specification are to be understood as referring to percentages by weight relative to the total composition. Unless otherwise stated, the amounts given are based on the effective weight of the material.

[0017] In one aspect, the present disclosure relates to antioxidant skin care compositions that effectively treat, prevent and / or reduce free radical damage to the user's skin. It has been discovered that the combined addition of pyrrolidone carboxylic acid and / or sodium PCA and / or niacinamide / vitamin B3 with vitamin E (e.g., alpha-tocopherol) and a thiourea derivative of histidine (e.g., malthionein) can provide unexpectedly enhanced protection to the skin from damage caused by reactive oxygen species.

[0018] In one aspect, the present invention provides a skin care composition (Composition 1.0) comprising vitamin E (e.g., α-tocopherol), a thiourea derivative of histidine (e.g., malathione), a vitamin B3 compound (e.g., niacinamide), and optionally pyrrolidone carboxylic acid and / or a salt thereof (e.g., sodium PCA).

[0019] For example, the present disclosure includes:

[0020] 1.1. The skin care composition of composition 1.0, wherein the vitamin E is vitamin E acetate or vitamin E succinate, or vitamin E acetate.

[0021] 1.2. Any of the preceding compositions, wherein vitamin E is selected from α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, tocopherol acetate, tocopherol phosphate, natural extracts rich in vitamin E derivatives, and combinations thereof.

[0022] 1.3. The aforementioned composition, wherein the vitamin E is α-tocopherol or a surface-acceptable salt thereof.

[0023] 1.4. Any of the preceding compositions, wherein vitamin E is present in an amount by weight based on the total weight of the skin care composition: 0.1% to 5%, for example, 0.2% to 2%, or 0.2% to 1.5%, or 0.2% to 1.25%, or 0.2% to 1%, or 0.2% to 0.9%, or 0.2% to 0.8%, or 0.2% to 0.7%, or 0.2% to 0.6%, or 0.2% to 0.5%, or 0.2% to 0.4%, or 0.2% to 0.3%, or about 2%, or about 1.5%, or about 1.25%, or about 1%, or about 0.9%, or about 0.8%, or about 0.7%, or about 0.6%, or about 0.5%, or about 0.4%, or about 0.3%, or any range or sub-range formed therefrom.

[0024] 1.5. Any of the preceding compositions, wherein the thiourea derivative of histidine is ergothioneine.

[0025] 1.6. The aforementioned composition, wherein ergothioneine ("EGT") is present in an amount of 0.001% to 2%, such as 0.001% to 2%, or 0.001% to 1.5%, or 0.001% to 1.25%, or 0.001% to 1%, or 0.001% to 0.5%, or 0.001% to 0.1% by weight based on the total weight of the skin care composition (e.g., wherein weight refers to the effective weight of EGT). , or 0.001% to 0.05%, or 0.001% to 0.01%, or 0.001% to 0.009%, or 0.001% to 0.008%, or 0.001% to 0.0075%, or 0.001% to 0.007%, or 0.001% to 0.0065%, or 0.001% to 0.006%, or 0.001% to 0.0055%, or 0.001% to 0.005% , or 0.001% to 0.0045%, or 0.001% to 0.004%, or 0.001% to 0.0035%, or 0.001% to 0.003%, or 0.001% to 0.0025%, or 0.001% to 0.002%, or 0.001% to 0.0015%, or about 0.0015%, or about 0.002%, or about 0.0025%, or about 0.003%, or about 0.001%. 0.0035%, or about 0.004%, or about 0.0045%, or about 0.005%, or about 0.0055%, or about 0.006%, or about 0.0065%, or about 0.007%, or about 0.0075%, or about 0.008%, or about 0.009%, or about 0.01%, or about 0.05%, or about 0.1%, or about 0.5%, or about 1%, or any range or sub-range formed therefrom.

[0026] 1.7. Any of the preceding compositions, wherein the formula of vitamin B3 comprises:

[0027]

[0028] wherein R is –CONH2 (ie, nicotinamide), –COOH (ie, nicotinic acid) or –CH2OH (ie, nicotinyl alcohol); derivatives thereof and / or salts thereof.

[0029] 1.8. Any of the foregoing compositions, wherein the vitamin B3 is selected from nicotinic acid esters, non-vasodilatory nicotinic acid esters, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids (e.g., linear or branched, cyclic or acyclic, saturated or unsaturated (including aromatic), and substituted or unsubstituted), nicotinic acid N-oxide and nicotinamide N-oxide, tocopheryl nicotinate, and inositol hexanicotinate. Examples of nicotinamide derivatives include nicotinyl amino acids, derived from, for example, the reaction of an activated nicotinic acid compound (e.g., nicotinic acid azide or nicotinyl chloride) with an amino acid; and nicotinyl alcohol esters of organic carboxylic acids (e.g., C1-C18). Specific examples of such derivatives include nicotinyl glycine and nicotinyl hydroxamic acid, which have the following chemical structures:

[0030]

[0031] Additional niacinamide derivatives include nicotinyl alcohol esters, such as nicotinyl alcohol esters of carboxylic acids, salicylic acid, acetic acid, glycolic acid, palmitic acid, etc. Additional examples of niacinamide derivatives include 2-chloronicotinamide, 6-aminonicotinamide, 6-methylnicotinamide, n-methyl-nicotinamide, n,n-diethylnicotinamide, n-(hydroxymethyl)-nicotinamide, quinolinic acid imide, nicotinanilide, n-benzylnicotinamide, n-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methylisonicotinic acid, thionicotinamide, propionylbenzylamide isoniazid, 1-(3-pyridylmethyl)urea, 2-mercaptonicotinic acid, nicomol, niaprazine, and combinations thereof.

[0032] 1.9. Any of the preceding compositions, wherein the vitamin B3 compound is present in an amount by weight based on the total weight of the composition: 0.1% to 5%, for example 0.2% to 4.75%, or 0.2% to 4.5%, or 0.2% to 4.25%, or 0.2% to 4%, or 0.2% to 3.75%, or 0.2% to 3.5%, or 0.2% to 3.25%, or 0.2% to 3%, or 0.2% to 2.75%, or 0.2% to 2.5%, or 0.2% to 2.25%, or 0.2% to 3.75%, or 0.2% to 3.5%, or 0.2% to 3.25%, or 0.2% to 3%. .2% to 2%, or 0.2% to 1.75%, or 0.2% to 1.5%, or 0.2% to 1.25%, or about 0.2% to 1%, or about 4.75%, or about 4.5%, or about 4.25%, or about 4%, or about 3.75%, or about 3.5%, or about 3.25%, or about 3%, or about 2.75%, or about 2.5%, or about 2.25%, or about 2%, or about 1.75%, or about 1.5%, or about 1.25%, or about 1%, or about 0.5%, or any range or subrange thereof. The total amount of vitamin B present in the skin care composition can be from about 0.1% to about 5% by weight, based on the total weight of the skin care composition.For example, the skin care composition can include vitamin B in a total amount of about 0.1% to about 5%, about 0.1% to about 4%, about 0.1% to about 3%, about 0.1% to about 2%, about 0.1% to about 1%, about 0.1% to about 0.7% based on the total weight of the skin care composition; about 0.3% to about 5%, about 0.3% to about 4%, about 0.3% to about 3%, about 0.1% to about 2%, about 0.3% to about 1%, about 0.3% to about 0.7%; about 0.5% to about 5%, about 0.5% to about 4%, about 0.5% to about 3%, about 0.5% to about 2%, about 0.5% to about 1%, about 0.5% to about 0.7%; about 0.7% to about 5%, about 0.7% to about 0.7%; % to about 4 wt%, about 0.7 wt% to about 3 wt%, about 0.7 wt% to about 2 wt%, about 0.7 wt% to about 1 wt%; about 1 wt% to about 5 wt%, about 1 wt% to about 4 wt%, about 1 wt% to about 3 wt%, about 1 wt% to about 2 wt%, about 1 wt% to about 1.5 wt%, about 1 wt% to about 1.25 wt%; about 1.25 wt% to about 5 wt%, about 1.25 wt% to about 4 wt%, about 1.25 wt% to about 3 wt%, about 1.25 wt% to about 2 wt%; about 1.5 wt% to about 5 wt%, about 1.5 wt% to about 4 wt%, about 1.5 wt% to about 3 wt%, about 1.5 wt% to about 2 wt%; about 2 wt% to about 5 wt%, about 2 wt% to about 4 wt%, about 2 wt% to about 3 wt%; about 3 wt% to about 5 wt%, about 3 wt% to about 4 wt%, or any range or subrange thereof.

[0033] 1.10. The skin care composition of any of the preceding compositions wherein the vitamin B3 compound comprises niacinamide.

[0034] 1.11. The skin care composition of any of the preceding compositions, wherein the skin care composition comprises pyrrolidone carboxylic acid and / or a salt thereof (eg, sodium PCA). In certain preferred embodiments, the pyrrolidone carboxylic acid and / or a salt thereof comprises L-pyrrolidone carboxylic acid and / or a salt thereof.

[0035] 1.12. The aforementioned skin care composition, wherein the pyrrolidone carboxylic acid and / or its salt is present at 0.1% to 5% by weight (e.g., 0.5% to 2% by weight, or 0.5% to 1.5%, or 0.5% to 1.25%, or 0.5% to 1%, or 0.75% to 1.25%) (e.g., about 0.5% by weight) (e.g., about 1% by weight) (e.g., about 1.5% by weight) (e.g., about 2% by weight) relative to the total composition. In some embodiments, the skin care composition comprises pyrrolidone carboxylic acid and / or its salt in an amount of about 0.1% to about 5% by weight, based on the total weight of the personal care composition. For example, the total amount of pyrrolidone carboxylic acid and / or salt thereof present in the skin care composition can be from about 0.1 wt % to about 5 wt %, from about 0.1 wt % to about 4 wt %, from about 0.1 wt % to about 3 wt %, from about 0.1 wt % to about 2 wt %, from about 0.1 wt % to about 1 wt %, from about 0.1 wt % to about 0.7 wt %; from about 0.3 wt % to about 5 wt %, from about 0.3 wt % to about 4 wt %, from about 0.3 wt % to about 3 wt %, from about 0.1 wt % to about 2 wt %, from about 0.3 wt % to about 1 wt %, from about 0.3 wt % to about 0.7 wt %; from about 0.5 wt % to about 5 wt %, from about 0.5 wt % to about 4 wt %, from about 0.5 wt % to about 3 wt %, from about 0.5 wt % to about 2 wt %, from about 0.5 wt % to about 1 wt %, from about 0.5 wt % to about 0.7 wt %; .7 wt % to about 4 wt %, about 0.7 wt % to about 3 wt %, about 0.7 wt % to about 2 wt %, about 0.7 wt % to about 1 wt %; about 1 wt % to about 5 wt %, about 1 wt % to about 4 wt %, about 1 wt % to about 3 wt %, about 1 wt % to about 2 wt %, about 1 wt % to about 1.5 wt %, about 1 wt % to about 1.25 wt %; about 1.25 wt % to about 5 wt %, about 1.25 wt % to about 4 wt %. %, about 1.25 wt % to about 3 wt %, about 1.25 wt % to about 2 wt %; about 1.5 wt % to about 5 wt %, about 1.5 wt % to about 4 wt %, about 1.5 wt % to about 3 wt %, about 1.5 wt % to about 2 wt %; about 2 wt % to about 5 wt %, about 2 wt % to about 4 wt %, about 2 wt % to about 3 wt %; about 3 wt % to about 5 wt %, about 3 wt % to about 4 wt %, or any range or sub-range thereof.

[0036] 1.13. Any of the preceding skin care compositions wherein the skin care composition comprises water.

[0037] 1.14. The aforementioned skin care composition, wherein the amount of water is from about 25 wt % to about 96 wt %, based on the total weight of the skin care composition, for example, about 30 wt %, about 40 wt %, about 50 wt %, about 60 wt %, about 70 wt %, about 80 wt %, about 90 wt %, about 96 wt %, or any range or sub-range thereof. For example, the total amount of water present in the skin care composition can be from about 25% to about 96% by weight, from about 40% to about 96% by weight, from about 50% to about 96% by weight, from about 60% to about 96% by weight, from about 70% to about 96% by weight, from about 80% to about 96% by weight, from about 85% to about 96% by weight, based on the total weight of the skin care composition; from about 25% to about 90% by weight, from about 40% to about 90% by weight; from about 50% to about 90% by weight, from about 60% to about 90% by weight, from about 70% to about 96% by weight, from about 80% to about 96% by weight, from about 85% to about 96% by weight; % to about 80 weight %, about 40 weight % to about 80 weight %, about 50 weight % to about 80 weight %, about 60 weight % to about 80 weight %, about 70 weight % to about 80 weight %; about 25 weight % to about 70 weight %, about 40 weight % to about 70 weight %, about 50 weight % to about 70 weight %, about 60 weight % to about 70 weight %; about 25 weight % to about 60 weight %, about 40 weight % to about 60 weight %, about 50 weight % to about 60 weight %; about 25 weight % to about 50 weight %, about 40 weight % to about 50 weight %, about 50 weight % to about 50 weight %, about 60 weight % to about 50 weight %, or any range or sub-range thereof.

[0038] 1.15. Any of the preceding compositions wherein the composition further comprises a gelling agent, an additional antioxidant, a fragrance, or a combination thereof.

[0039] 1.16. Any of the preceding compositions, wherein the skin care composition is topically delivered to the skin in a form selected from the group consisting of serums, creams, moisturizers, masks, cleansers, oils, salves, lotions, gels, ointments, pastes, facial make-up, toners, fragrances, and balms (e.g., lip balms).

[0040] 1.17. Any of the preceding compositions wherein the composition further comprises an additional vitamin selected from the group consisting of vitamin C (eg, vitamin C salts and derivatives), vitamin D, vitamin K, and combinations thereof.

[0041] 1.18. Any of the foregoing skin care compositions, wherein the composition comprises one or more amino acids selected from the group consisting of arginine, lysine, serine, citrulline, ornithine, creatine, histidine, diaminobutyric acid, diaminopropionic acid, alanine, aminobutyric acid, asparagine, cysteine, cystine, glutamine, glycine, hydroxyproline, isoleucine, leucine, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, and salts thereof, and combinations thereof. The skin care composition may comprise the one or more amino acids in an amount of about 0.01 wt % to about 5 wt %, based on the total weight of the skin care composition.In some embodiments, the skin care composition can include an amino acid in an amount of about 0.01% to about 2% by weight, about 0.01% to about 1.7% by weight, about 0.01% to about 1.4% by weight, about 0.01% to about 1.2% by weight, about 0.01% to about 1% by weight, about 0.01% to about 0.8% by weight, about 0.01% to about 0.6% by weight, about 0.01% to about 0.4% by weight, about 0.01% to about 0.2% by weight, about 0.01% to about 0.1% by weight, about 0.01% to about 0.05% by weight, based on the total weight of the skin care composition. % by weight; about 0.05 % by weight to about 3 % by weight, about 0.05 % by weight to about 2 % by weight, about 0.05 % by weight to about 1.7 % by weight, about 0.05 % by weight to about 1.4 % by weight, about 0.05 % by weight to about 1.2 % by weight, about 0.05 % by weight to about 1 % by weight, about 0.05 % by weight to about 0.8 % by weight, about 0.05 % by weight to about 0.6 % by weight, about 0.05 % by weight to about 0.4 % by weight, about 0.05 % by weight to about 0.2 % by weight, about 0.05 % by weight to about 0.1 % by weight; about 0.1 % by weight to about 3 % by weight, about 0.1 % by weight to about 2 % by weight, about 0.1 % by weight to about 1 .7 wt %, about 0.1 wt % to about 1.4 wt %, about 0.1 wt % to about 1.2 wt %, about 0.1 wt % to about 1 wt %, about 0.1 wt % to about 0.8 wt %, about 0.1 wt % to about 0.6 wt %, about 0.1 wt % to about 0.4 wt %, about 0.1 wt % to about 0.2 wt %; about 0.3 wt % to about 3 wt %, about 0.3 wt % to about 2 wt %, about 0.3 wt % to about 1.7 wt %, about 0.3 wt % to about 1.4 wt %, about 0.3 wt % to about 1.2 wt %, about 0.3 wt % to about 1 wt %, about 0.3 wt % to about 0.8 wt %, about 0.3 wt % to about 0.6 wt %; about 0.6 wt % to about 3 wt %, about 0.6 wt % to about 2 wt %, about 0.6 wt % to about 1.7 wt %, about 0.6 wt % to about 1.4 wt %, about 0.6 wt % to about 1.2 wt %, about 0.6 wt % to about 1 wt %; about 1 wt % to about 3 wt %, about 1 wt % to about 2 wt %, about 1 wt % to about 1.7 wt %, about 1 wt % to about 1.4 wt %, about 1 wt % to about 1.2 wt %; about 1.5 wt % to about 3 wt %, about 1.5 wt % to about 2 wt %, about 2 wt % to about 3 wt %, or any range or sub-range thereof.

[0042] 1.19. The total amount of amino acids present in the skin care composition can be from about 0.1% to about 7% by weight, based on the total weight of the skin care composition. For example, the total amount of amino acids in the skin care composition can be from about 0.1% to about 6%, from about 0.1% to about 5%, from about 0.1% to about 3%, from about 0.1% to about 2%, from about 0.1% to about 1.7%, from about 0.1% to about 1.4%, from about 0.1% to about 1.2%, from about 0.1% to about 1%, from about 0.1% to about 0.8%, from about 0.1% to about 0.6%, from about 0.1% to about 0.6%, from about 0.1% to about 0.6%, from about 0.1% to about 0.6%, from about 0.1% to about 0.6%, from about 0.1% to about 0.5 ... %, about 0.1 wt % to about 0.4 wt %, about 0.1 wt % to about 0.2 wt %; about 0.3 wt % to about 7 wt %, about 0.3 wt % to about 5 wt %, about 0.3 wt % to about 3 wt %, about 0.3 wt % to about 2 wt %, about 0.3 wt % to about 1.7 wt %, about 0.3 wt % to about 1.4 wt %, about 0.3 wt % to about 1.2 wt %, about 0.3 wt % to about 1 wt %, about 0.3 wt % to about 0.8 wt %, about 0.3 wt % to about 0. 6 wt %; about 0.6 wt % to about 7 wt %, about 0.6 wt % to about 5 wt %, about 0.6 wt % to about 3 wt %, about 0.6 wt % to about 2 wt %, about 0.6 wt % to about 1.7 wt %, about 0.6 wt % to about 1.4 wt %, about 0.6 wt % to about 1.2 wt %, about 0.6 wt % to about 1 wt %; about 1 wt % to about 7 wt %, about 1 wt % to about 5 wt %, about 1 wt % to about 3 wt %, about 1 wt % to about 2 wt %, about 1 wt % to about 1. 7 weight %, about 1 weight % to about 1.4 weight %, about 1 weight % to about 1.2 weight %; about 1.5 weight % to about 7 weight %, about 1.5 weight % to about 5 weight %, about 1.5 weight % to about 3 weight %, about 1.5 weight % to about 2 weight %, about 2 weight % to about 7 weight %, about 2 weight % to about 5 weight %, about 2 weight % to about 3 weight %; about 3 weight % to about 7 weight %, about 3 weight % to 5 weight %, about 4 weight % to about 7 weight %, about 4 weight % to 6 weight %, or any range or sub-range thereof.

[0043] 1.20. The aforementioned skin care composition, wherein the composition comprises taurine, arginine and glycine. The aforementioned skin care composition, wherein the weight ratio of taurine:arginine:glycine is (1.5 to 69):(0.5 to 40):(0.5 to 1.5), respectively. For example, the skin care composition can be formulated to have a weight ratio of taurine to arginine to glycine (taurine:arginine:glycine) of about 85:45:1 to about 45:24:1. In some embodiments, the weight ratio of taurine to arginine to glycine of the skin care composition is about 80:42:1 to about 50:30:1; about 75:40:1 to about 55:29:1; about 70:37:1 to about 60:31:1, or any range or subrange thereof.

[0044] 1.21. The aforementioned skin care composition wherein the weight ratio of taurine:arginine:glycine is approximately (65):(34):(1), respectively.

[0045] 1.22. Any of the preceding skin care compositions, wherein the skin care composition comprises an additional ingredient selected from the group consisting of carnosine, cica (asiatica sideroside), hyaluronic acid and its salts (e.g., sodium hyaluronate), magnesium sulfate, sugar isomers, ketocarotenoids (e.g., astaxanthin), nicotinamide adenine dinucleotide (NAD), and combinations of two or more thereof.

[0046] 1.23. Any of the preceding skin care compositions further comprising a topically acceptable carrier.

[0047] 1.24. Any of the preceding skin care compositions wherein one or more ingredients are encapsulated in a delivery vesicle (eg, a multilamellar vesicle (MLV)).

[0048] 1.25. The aforementioned skin care composition, wherein the MLV comprises a liposomal amount of polyglyceryl-10 dioleate and at least one of polyglyceryl-10 dilinoleate or polyglyceryl-10 dipalmitate, wherein the weight ratio of polyglyceryl-10 dioleate to at least one of polyglyceryl-10 dilinoleate or polyglyceryl-10 dipalmitate is 300:1 to 5:1.

[0049] 1.26. Any of the preceding skin care compositions wherein the MLV comprises one or more ingredients selected from the group consisting of polyglyceryl-10 dilinoleate, polyglyceryl-10 dipalmitate, polyglyceryl-10 dioleate, caprylic / capric triglyceride, and combinations thereof.

[0050] 1.27. Any of the preceding skin care compositions wherein the skin care composition is delivered via transdermal injection (eg, mesotherapy).

[0051] 1.28. Any of the foregoing skin care compositions, further comprising hyaluronic acid (HA). The amount of hyaluronic acid in the skin care composition may be from about 0.5% to about 5% by weight, based on the total weight of the skin care composition. For example, the total amount of hyaluronic acid in the skin care composition may be from about 0.5% to about 5% by weight, from about 0.5% to about 4% by weight, from about 0.5% to about 3% by weight, from about 0.5% to about 2% by weight, from about 0.5% to about 1.5% by weight, from about 0.5% to about 1% by weight, based on the total weight of the skin care composition; from about 0.75% to about 5% by weight, from about 0.75% to about 4% by weight, from about 0.75% to about 3% by weight, from about 0.75% to about 2% by weight, from about 0.75% to about 1.5% by weight, from about 0.5% to about 1% by weight; % by weight; about 1 % to about 5 % by weight, about 1 % to about 4 % by weight, about 1 % to about 3 % by weight, about 1 % to about 2 % by weight, about 1 % to about 1.5 % by weight; about 1.5 % to about 5 % by weight, about 1.5 % to about 4 % by weight, about 1.5 % to about 3 % by weight, about 1.5 % to about 2 % by weight; about 2 % to about 5 % by weight, about 2 % to about 4 % by weight, about 2 % to about 3 % by weight; about 3 % to about 5 % by weight, about 3 % to about 4 % by weight, or any range or sub-range thereof.

[0052] 1.29. The aforementioned composition wherein the HA is low molecular weight HA (eg, ≤ 300 kDA on average).

[0053] 1.30. The aforementioned composition, wherein the molecular weight (MW) of the hyaluronic acid is about 100,000 Da or less. In some embodiments, the molecular weight of the hyaluronic acid is about 10 kDa to about 75 kDa, about 25 kDa to 75 kDa, about 35 kDa to about 75 kDa, about 40 kDa to about 75 kDa, about 45 kDa to about 75 kDa, about 50 kDa to about 75 kDa, about 55 kDa to about 75 kDa, about 60 kDa to about 75 kDa; about 10 kDa to about 65 kDa, about 25 kDa to 65 kDa, about 35 kDa to about 65 kDa, about 40 kDa to about 65 kDa, about 45 kDa to about 65 kDa, about 50 kDa to about 65 kDa, about 55 kDa to about 65 kDa; about 10 kDa to about 60 kDa, about 25 kDa to 60 kDa, about 35 kDa to about 65 kDa, about kDa to about 60 kDa, about 40 kDa to about 60 kDa, about 45 kDa to about 60 kDa, about 50 kDa to about 60 kDa; about 10 kDa to about 55 kDa, about 25 kDa to 55 kDa, about 35 kDa to about 55 kDa, about 40 kDa to about 55 kDa, about 45 kDa to about 55 kDa; about 10 kDa to about 50 kDa, about 25 kDa to 50 kDa, about 35 kDa to about 50 kDa, about 40 kDa to about 50 kDa; about 10 kDa to about 45 kDa, about 25 kDa to 45 kDa; about 10 kDa to about 40 kDa, about 25 kDa to 40 kDa, about 30 kDa to about 40 kDa, or any range or sub-range thereof. In at least one embodiment, the skin care composition comprises hyaluronic acid having a molecular weight of about 50 kDa.

[0054] 1.31. Any of the foregoing skin care compositions, comprising:

[0055] taurine, arginine and glycine, wherein the weight ratio of taurine to arginine to glycine (taurine:arginine:glycine) of the skin care composition is (1.5 to 69):(0.5 to 40):(0.5 to 1.5), respectively (e.g., the weight ratio is about (65):(34):(1), respectively);

[0056] ·Ethioneine (EGT);

[0057] alpha-tocopherol; and

[0058] Vitamin B3 / Niacinamide.

[0059] 1.32. Any of the preceding skin care compositions, comprising:

[0060] taurine, arginine and glycine, wherein the weight ratio of taurine to arginine to glycine (taurine:arginine:glycine) of the skin care composition is (1.5 to 69):(0.5 to 40):(0.5 to 1.5), respectively (e.g., the weight ratio is about (65):(34):(1), respectively);

[0061] ·Ethioneine (EGT);

[0062] alpha-tocopherol; and

[0063] - Pyrrolidonecarboxylic acid and / or its salts (eg, sodium PCA).

[0064] 1.33. Any of the foregoing skin care compositions, comprising:

[0065] taurine, arginine and glycine, wherein the weight ratio of taurine to arginine to glycine (taurine:arginine:glycine) of the skin care composition is (1.5 to 69):(0.5 to 40):(0.5 to 1.5), respectively (e.g., the weight ratio is about (65):(34):(1), respectively);

[0066] ·Ethioneine (EGT);

[0067] α-Tocopherol;

[0068] Pyrrolidone carboxylic acid and / or its salts (e.g., sodium PCA); and

[0069] Vitamin B3 / Niacinamide.

[0070] 1.34. Any of the preceding skin care compositions, comprising:

[0071] ·Ethioneine (EGT);

[0072] alpha-tocopherol; and

[0073] pyrrolidonecarboxylic acid and / or its salts (e.g., sodium PCA),

[0074] The weight ratio of α-tocopherol to EGT to pyrrolidone carboxylic acid and / or its salt (α-tocopherol:EGT:pyrrolidone carboxylic acid and / or its salt) of the skin care composition is (0.5 to 2):(0.5 to 20):(0.5 to 20) (e.g. 1:1:1) (e.g. 1:1:2) (e.g. 1:10:10), respectively, wherein the weight ratios are given relative to the raw material weight % of the ingredients.

[0075] 1.35. Any of the foregoing compositions, comprising:

[0076] ·Ethioneine (EGT);

[0077] alpha-tocopherol; and

[0078] Niacinamide,

[0079] The weight ratios of α-tocopherol:EGT:niacinamide are (0.5 to 2):(0.5 to 20):(0.5 to 20) (e.g. 1:1:1) (e.g. 1:1:2) (e.g. 1:1:3) (e.g. 1:2:1) (e.g. 1:3:1) (e.g. 2:1:1) and (e.g. 3:1:1), respectively, wherein the weight ratios are given relative to the raw material weight % of the ingredients.

[0080] 1.36. Any of the foregoing compositions, comprising:

[0081] ·Ethioneine (EGT);

[0082] alpha-tocopherol; and

[0083] pyrrolidonecarboxylic acid and / or its salts (e.g., sodium PCA),

[0084] wherein the weight ratio of α-tocopherol:EGT:pyrrolidone carboxylic acid and / or its salt of the skin care composition is (50 to 250):(0.5 to 20):(50 to 250) (e.g. 50:1:50, 50:1:100, 50:1:150, 50:1:200, 50:1:250, 100:1:50, 100:1:100, 100:1:150, 100:1:200, 100:1:250). 1:200, 250:1:250, or any range or subrange thereof), wherein the weight ratio is based on the weight % of the active material of the ingredient.

[0085] 1.37. Any of the preceding skin care compositions, comprising:

[0086] ·Ethioneine (EGT);

[0087] alpha-tocopherol; and

[0088] Niacinamide,

[0089] wherein the weight ratio of α-tocopherol to EGT to niacinamide (α-tocopherol: EGT: niacinamide) of the skin care composition is (50 to 250): (0.5 to 20): (100 to 500) (e.g., 50:1:100, 50:1:150, 50:1:200, 50:1:250, 50:1:300, 50:1:350, 50:1:400, respectively). 0, 50:1:450, 50:1:500, 100:1:100, 100:1:150, 100:1:200, 100:1:250, 100:1:300, 100:1:350, 100:1:400, 100:1:450, 100:1:500, 150:1:100, 150:1:150, 150:1:2 00, 150:1:250, 150:1:300, 150:1:350, 150:1:400, 150:1:450, 150:1:500, 200:1:100, 200:1:150, 200:1:200, 200:1:250, 200:1:300, 200:1:350, 200:1:400, 200: 1:450, 200:1:500, 250:1:100, 250:1:150, 250:1:200, 250:1:250, 250:1:300, 250:1:350, 250:1:400, 250:1:450, 250:1:500, or any range or sub-range thereof), wherein the weight ratio is based on the active material weight % of the ingredient.

[0090] 1.38. Any of the foregoing skin care compositions, comprising:

[0091] ·Ethioneine (EGT);

[0092] α-Tocopherol;

[0093] Niacinamide; and

[0094] - Pyrrolidonecarboxylic acid and / or its salts (eg, sodium PCA).

[0095] 1.39. A skin care composition according to any of the preceding compositions, comprising (wt %):

[0096]

[0097] * Columns A, B and D: Unless otherwise stated, amounts are given in effective % by weight.

[0098] ** Column C: Amounts given in % by weight of raw material.

[0099] 1.40. Any of the preceding skin care compositions wherein the skin care composition is delivered via transdermal injection (eg, mesenchymal therapy).

[0100] 1.41. Any of the preceding skin care compositions wherein one or more ingredients are encapsulated in a delivery vesicle (eg, a multilamellar vesicle (MLV)).

[0101] 1.42. Any of the foregoing skin care compositions, wherein one or more ingredients are encapsulated in a delivery vesicle (e.g., a multilamellar vesicle (MLV)), wherein 0.1% to 15% (e.g., about 10%) of the ingredients in the final formulation are encapsulated in the delivery vesicle (e.g., MLV).

[0102] 1.43. The aforementioned composition, wherein the delivery vesicle is an MLV, and wherein the MLV encapsulates the following components:

[0103] i. Niacinamide;

[0104] ii.Carnosine;

[0105] iii. α-tocopherol; and

[0106] iv. Taurine, arginine and glycine.

[0107] 1.44. The foregoing compositions wherein the weight ratios of taurine, arginine, and glycine:niacinamide:carnosine:α-tocopherol are approximately 2:1:1:1 or 2:2:1:1, respectively.

[0108] 1.45. Any of the preceding skin care compositions, wherein the skin care composition is in a form selected from the group consisting of serums, creams, moisturizers, masks, cleansers, oils, salves, lotions, gels, ointments, pastes, facial makeup, and balms (e.g., lip balms).

[0109] 1.46. Any of the preceding compositions wherein the composition comprises a thickener.

[0110] 1.47. Any of the preceding compositions wherein the thickener comprises a gum optionally selected from the group consisting of xanthan gum, carrageenan, and combinations thereof.

[0111] 1.48. Any of the preceding compositions wherein the composition comprises a humectant, optionally wherein the humectant is selected from glycerin, sorbitol, and combinations thereof.

[0112] 1.49. Any of the preceding compositions comprising an additional antioxidant selected from the group consisting of flavonoids, phytoncide, carnosine, ascorbic acid, tocotrienols, lipoic acid, carotenoids, melatonin, and any combination thereof.

[0113] 1.50. Any of the foregoing compositions, further comprising an anti-inflammatory agent selected from the group consisting of dexamethasone, prednisolone, corticosterone, budesonide, sulfasalazine, mesalamine, cetirizine, diphenhydramine, antipyrine, methyl salicylate, loratadine, thymol, carvacrol, bisabolol, allantoin, eucalyptol, phenazone, propyphenazone, nonsteroidal anti-inflammatory drugs (NSAIDs), and any combination thereof.

[0114] 1.51. Any of the preceding compositions further comprising an antipruritic agent, wherein the antipruritic agent is selected from the group consisting of methylsulfonylmethane, sodium bicarbonate, calamine, allantoin, kaolin, peppermint, tea tree oil, camphor, menthol, and hydrocortisone, and any combination thereof.

[0115] 1.52. Any of the foregoing skin care compositions, wherein the skin care composition is formulated to have a weight ratio of alpha-tocopherol to EGT of about 6:1 to about 1:6. Preferably, the skin care composition has a weight ratio of alpha-tocopherol to EGT of about 6:1 to about 1:6, about 5:1 to about 1:6, about 4:1 to about 1:6, about 3:1 to about 1:6, about 2:1 to about 1:6, about 1:1 to about 1:6; about 6:1 to about 1:5, about 5:1 to about 1:5, about 4:1 to about 1:5, about 3:1 to about 1:5, about 2:1 to about 1:5, about 1:1 to about 1:5; about 6:1 to about 1:4, about 5:1 to about 1:4, about 4:1 to about 1:4, about 3:1 to about 1:4, about 2:1 to about 1:4, From about 1:1 to about 1:4; from about 6:1 to about 1:3, from about 5:1 to about 1:3, from about 4:1 to about 1:3, from about 3:1 to about 1:3, from about 2:1 to about 1:3, from about 1:1 to about 1:3; from about 6:1 to about 1:2, from about 5:1 to about 1:2, from about 4:1 to about 1:2, from about 3:1 to about 1:2, from about 2:1 to about 1:2, from about 1:1 to about 1:2; from about 6:1 to about 1:1, from about 5:1 to about 1:1, from about 4:1 to about 1:1, from about 3:1 to about 1:1, from about 2:1 to about 1:1, about 1:1, or any range or sub-range thereof.

[0116] 1.53. Additionally or alternatively, the skin care composition may be formulated such that the weight ratio of alpha-tocopherol to niacinamide and / or EGT to niacinamide is from about 1:1 to about 1:11. In some embodiments, the weight ratio of alpha-tocopherol to niacinamide and / or EGT to niacinamide of the skin care composition is from about 1:1 to about 1:11, from about 1:1 to about 1:9, from about 1:1 to about 1:7, from about 1:1 to about 1:6, from about 1:1 to about 1:5, from about 1:1 to about 1:4, from about 1:1 to about 1:3; from about 1:2 to about 1:11, from about 1:2 to about 1:9, from about 1:2 to about 1:7, from about 1:2 to about 1:6, from about 1:2 to about 1:5, from about 1:2 to about 1:4, from about 1:2 to about 1:3; from about 1:3 to about 1:11, from about 1:3 to about 1:9, from about 1:3 to about 1:7, from about 1:3 to about 1:6, from about 1:3 to about 1:5, from about 1:3 to about 1:4, about 1:3, or any range or sub-range thereof.

[0117] 1.54. Additionally or alternatively, the skin care composition may be formulated such that the weight ratio of alpha-tocopherol to pyrrolidone carboxylic acid and / or its salts and / or EGT to pyrrolidone carboxylic acid and / or its salts is from about 1:1 to about 1:11. In some embodiments, the weight ratio of alpha-tocopherol to pyrrolidone carboxylic acid and / or its salt and / or EGT to pyrrolidone carboxylic acid and / or its salt of the skin care composition is from about 1:1 to about 1:11, from about 1:1 to about 1:9, from about 1:1 to about 1:7, from about 1:1 to about 1:6, from about 1:1 to about 1:5, from about 1:1 to about 1:4, from about 1:1 to about 1:3; from about 1:2 to about 1:11, from about 1:2 to about 1:9, from about 1:2 to about 1:7, from about 1:2 to about 1:6, from about 1:2 to about 1:5, from about 1:2 to about 1:4, from about 1:2 to about 1:3; from about 1:3 to about 1:11, from about 1:3 to about 1:9, from about 1:3 to about 1:7, from about 1:3 to about 1:6, from about 1:3 to about 1:5, from about 1:3 to about 1:4, about 1:3, or any range or sub-range thereof.

[0118] 1.55. Any of the aforementioned skin care compositions, wherein the skin care composition comprises a weight ratio of α-tocopherol to EGT to pyrrolidone carboxylic acid and / or its salt (α-tocopherol:EGT:pyrrolidone carboxylic acid and / or its salt) of (0.5 to 2):(0.5 to 20):(1 to 20) (e.g. 1:1:1) (e.g. 1:1:2) (e.g. 1:10:10), respectively, wherein the weight ratio is based on the weight of the ingredients relative to the total weight of the composition.

[0119] 1.56. Any of the foregoing compositions, wherein the skin care composition comprises α-tocopherol:EGT:sodium PCA in a weight ratio of (50 to 250):(0.5 to 20):(50 to 250) (e.g., (200:1:200)), respectively, wherein the weight ratios are based on the weight percent of active material of the ingredients relative to the total weight of the composition. In certain embodiments, the skin care composition can be formulated such that the weight ratio of α-tocopherol to EGT to pyrrolidone carboxylic acid and / or a salt thereof (α-tocopherol:EGT:pyrrolidone carboxylic acid and / or a salt thereof) is from about 1:2:6 to about 1:0.5:1.5, from about 1:1.5:4 to about 1:0.75:2; from about 1:1.1:3.3 to about 1:0.9:2.7.

[0120] 1.57. Any of the foregoing skin care compositions, wherein the skin care composition comprises a weight ratio of α-tocopherol to EGT to niacinamide (α-tocopherol:EGT:niacinamide) of (0.5 to 2):(1 to 20):(1 to 20) (e.g., 1:1:1) (e.g., 1:1:2) (e.g., 1:1:3), respectively, wherein the weight ratios are based on the raw material weight % of the ingredients relative to the total weight of the composition. In certain embodiments, the skin care composition can be formulated to have a weight ratio of α-tocopherol to EGT to niacinamide (α-tocopherol:EGT:niacinamide) of about 1:2:6 to about 1:0.5:1.5, about 1:1.5:4 to about 1:0.75:2; about 1:1.1:3.3 to about 1:0.9:2.7.

[0121] 1.58. Any of the preceding compositions, wherein the skin care composition comprises a weight ratio of α-tocopherol to EGT to niacinamide (α-tocopherol:EGT:niacinamide) of (100 to 250):(0.5 to 5):(200 to 600) (e.g., 200:1:400), wherein the weight ratios are based on the active material weight % of the ingredients.

[0122] 1.59. Any of the preceding skin care compositions, wherein the skin care composition comprises:

[0123] Niacinamide (e.g., 0.5% to 5% by weight of the composition) (e.g., about 3% by weight);

[0124] alpha-tocopherol (e.g., 0.1% to 2% by weight of the composition) (e.g., about 0.5% by weight); and

[0125] • Ergothioneine (EGT) (eg, 0.001% to 0.005% by weight of the composition) (eg, about 0.0025% by weight).

[0126] 1.60. The aforementioned skin care composition, wherein the skin care composition further comprises:

[0127] Ascorbyl glucoside (e.g., 0.5% to 5% by weight of the composition) (e.g., about 2% by weight), wherein the ascorbyl glucoside is present in an amount preferably from about 1% to about 5%, from about 1% to about 4%, from about 1% to about 3%, from about 1% to about 2%; from about 2% to about 5%, from about 2% to about 4%, from about 2% to about 3%; from about 3% to about 5%, from about 3% to about 4%, or any range or subrange thereof, based on the total weight of the skin care composition; and

[0128] • Astaxanthin (eg, 0.001% to 0.05% by weight of the composition) (eg, about 0.01% by weight).

[0129] 1.61. Any of the preceding skin care compositions, wherein the skin care composition comprises:

[0130] ·Ethioneine (EGT);

[0131] α-Tocopherol;

[0132] Niacinamide (vitamin B);

[0133] Pyrrolidonecarboxylic acid and / or its salts (e.g., sodium PCA);

[0134] Hyaluronic acid (e.g., MW 50 kDa);

[0135] magnesium sulfate; and

[0136] Nicotinamide adenine dinucleotide (NAD).

[0137] In another aspect, the present disclosure provides a personal care composition (Composition 2.0), such as a skin care composition for inhibiting, treating or reducing damage to the skin caused by reactive oxygen species. In one aspect, the skin care composition used can be any one of Composition 1.0 et seq., etc.

[0138] In another aspect, the present disclosure provides a method for inhibiting, treating or reducing damage to the skin caused by reactive oxygen species (Method 1.0), wherein the method comprises administering an effective amount of any of Compositions 1.0 et seq. to a subject in need thereof.

[0139] 1.1 Method 1.0, wherein the skin care composition (eg, any of compositions 1.0 et seq.) is delivered by transdermal injection.

[0140] 1.2 Method 1.0, wherein the skin care composition is topically delivered to the skin using serums, creams, moisturizers, masks, cleansers, oils, salves, lotions, gels, ointments, pastes, facial make-up, toners, fragrances, and balms (e.g., lip balms).

[0141] In another aspect, the present disclosure provides a method of depositing a surface-active compound on the skin (Method 2.0), comprising applying to the skin an effective amount of any of the skin care compositions disclosed herein (e.g., any of Compositions 1 et seq.).

[0142] 2.1 Method 2.0, wherein the skin care composition (eg, any of compositions 1.0 et seq.) is delivered by transdermal injection.

[0143] 2.2 Method 2.0, wherein the skin care composition is topically delivered to the skin using serums, creams, moisturizers, masks, cleansers, oils, salves, lotions, gels, ointments, pastes, facial make-up, toners, fragrances, and balms (e.g., lip balms).

[0144] In another aspect, the present disclosure provides a method selected from the following (Method 3.0):

[0145] · Activate skin cells of subjects in need thereof;

[0146] · Enhancing cellular energy in skin cells (e.g., dermal cells) of a subject in need thereof;

[0147] Reducing or inhibiting cell damage (e.g., from reactive oxygen species, UV light damage) in a subject in need thereof; and

[0148] · performing cellular detoxification (e.g., in dermal cells) in a subject in need thereof,

[0149] Wherein any of the above methods comprises applying to the skin an effective amount of any of the skin care compositions disclosed herein (eg, any of Composition 1 et seq.).

[0150] 3.1 Method 3.0, wherein the skin care composition (eg, any of compositions 1.0 et seq.) is delivered by transdermal injection.

[0151] 3.2 Method 3.0, wherein the skin care composition is topically delivered to the skin using serums, creams, moisturizers, masks, cleansers, oils, salves, lotions, gels, ointments, pastes, facial make-up, toners, fragrances, and balms (e.g., lip balms).

[0152] In another aspect, the present disclosure provides a method selected from the group consisting of:

[0153] Treating redness and / or reducing the size of skin pores in a subject in need thereof;

[0154] Treat fine lines, wrinkles or scars in subjects who need it;

[0155] Treatments to increase the smoothness, hydration and / or elasticity of the skin of a subject in need thereof;

[0156] Reducing or inhibiting cell damage (e.g., from reactive oxygen species, UV light damage) in a subject in need thereof; and

[0157] · performing cellular detoxification (e.g., in dermal cells) in a subject in need thereof,

[0158] Wherein any of the above methods comprises applying to the skin an effective amount of any of the skin care compositions disclosed herein (eg, any of Composition 1 et seq.).

[0159] 4.1 Method 4.0, wherein the skin care composition (eg, any of compositions 1.0 et seq.) is delivered by transdermal injection.

[0160] 4.2 Method 4.0, wherein the skin care composition is topically delivered to the skin using serums, creams, moisturizers, masks, cleansers, oils, salves, lotions, gels, ointments, pastes, facial make-up, toners, fragrances, and balms (e.g., lip balms).

[0161] In some embodiments, the skin care composition (e.g., any of compositions 1.0 et seq.) comprises an oil selected from the group consisting of sunflower oil, olive oil, shea butter, jojoba oil, almond oil, grapeseed oil, rosehip seed oil, mink oil, castor oil, soybean oil, mineral oil, and combinations thereof, optionally wherein the oil is sunflower oil.

[0162] In some embodiments, the skin care composition (e.g., any of Composition 1.0 et seq.) comprises a thickener. In some embodiments, the thickener comprises a gum optionally selected from xanthan gum, carrageenan, and combinations thereof.

[0163] In some embodiments, the skin care composition (eg, any of Compositions 1.0 et seq.) comprises a humectant, optionally, wherein the humectant is selected from glycerin, sorbitol, and combinations thereof.

[0164] In some embodiments, the skin care composition (eg, any of compositions 1.0 et seq.) comprises water.

[0165] In some embodiments, the skin care composition (eg, any of compositions 1.0 et seq.) is free or substantially free of sulfates.

[0166] In some embodiments, the skin care composition (eg, any of Compositions 1.0 et seq.) further comprises a gelling agent, an additional antioxidant, a fragrance, or a combination thereof.

[0167] In some embodiments, the composition (eg, any of composition 1.0 et seq.) is in a form selected from the group consisting of a serum, a cream, a moisturizer, a mask, a cleanser, a facial makeup, and a balm (eg, a lip balm).

[0168] The composition of the present disclosure (e.g., any one of composition 1.0 et seq.) can be any type of personal care composition. In certain embodiments, the composition is any composition that can be formulated into a surface skin care preparation suitable for application to the skin. Examples of such compositions include, but are not limited to, serums, creams, moisturizers, facial masks, cleansers (e.g., facial cleansers), facial cosmetics, balms (e.g., lip balms), and cosmetics. The composition can include a single phase or can be a multiphase system, e.g., a system comprising a polar phase and an oil phase, optionally in the form of a stable emulsion. In certain aspects, the skin care composition of the present disclosure is formulated in a manner suitable for surface injection.

[0169] The composition of the present disclosure (e.g., any of composition 1.0 et seq.) can be liquid, semisolid or solid. The formulation can be provided in any suitable container, tube, or container with a porous lid, roll-on container, bottle, container with an open end, etc.

[0170] In some aspects, water may be present in the skin care compositions of the present disclosure (e.g., any of Compositions 1.0 et seq.). Water used to prepare commercial personal care compositions should be deionized and free of organic impurities. When incorporated into a formulation, water may constitute the balance of the composition and account for about 10% to about 90%, or about 10% to about 80%, by weight of the skin care composition. This amount of water includes the free water added plus the amount introduced with other materials such as glycerin, sorbitol, or any component of the present disclosure.

[0171] In some embodiments, the skin care compositions of the present disclosure (e.g., any of compositions 1.0 et seq.) may include one or more pH adjusters. When incorporated into a formulation, pH adjusters may include, but are not limited to, lactic acid, sodium hydroxide, and / or citric acid.

[0172] In some embodiments, the skin care composition (e.g., any of Compositions 1.0 et seq.) may also include a betaine zwitterionic surfactant. In some aspects, the betaine zwitterionic surfactant may be C8-C 16 Aminopropyl betaine, for example, cocamidopropyl betaine.

[0173] In some embodiments, the skin care compositions described herein (e.g., any of compositions 1.0 et seq.) may also include a nonionic block copolymer selected from Poloxamer 338, Poloxamer 407, Poloxamer 237, Poloxamer 217, Poloxamer 124, Poloxamer 184, Poloxamer 185, and combinations of two or more thereof.

[0174] As used herein, the term "effective amount" means the amount of active ingredient and / or skin care composition required to provide adequate protection against damage caused by or associated with reactive oxygen species.

[0175] As used herein, "substantially free" of a certain material can refer to a composition in which the material is present in an amount of less than 0.1 wt%, less than 0.05 wt%, less than 0.01 wt%, less than 0.005 wt%, less than 0.001 wt%, or less than 0.0001 wt%, based on the total weight of the composition.

[0176] As used herein, "skin care composition" means that the intended use may include a composition that promotes or improves the health, cleanliness, smell, appearance and / or attractiveness of the skin. For example, the skin care composition can be in the form of essences, creams, moisturizers, facial masks, cleansers, oils, salves, lotions, gels, ointments, pastes, facial cosmetics, toners, essences and balms (e.g., lip balms). The skin care composition of the present disclosure (e.g., any one of composition 1.0 and below) can be applied to the skin by the user or consumer surface. In some aspects, the skin care composition of the present disclosure can be applied by injection (e.g., subcutaneous injection or dermal injection). In some aspects, the skin care composition is intended to refer to a product for use in a home or professional setting.

[0177] In certain aspects, the skin care compositions of the present disclosure (e.g., any of Compositions 1.0 et seq.) may comprise one or more surface active compounds selected from antimicrobial agents, vitamins, drugs, fragrance materials, antioxidants, and other skin care ingredients.

[0178] As used herein, unless otherwise specified, "vitamin E" refers to a family of four isomers of tocopherol and four isomers of tocotrienol. All eight isomers of vitamin E have a 6-chromogenol ring structure and a side chain. Four tocopherols include fully saturated side chains, and include α-tocopherol, γ-tocopherol, β-tocopherol and δ-tocopherol. Four tocotrienols include unsaturated side chains, and include α-tocotrienol, γ-tocotrienol, β-tocotrienol and δ-tocotrienol. As used herein, unless otherwise specified, the term "vitamin E" may refer to any one or more of the eight isomers. For example, as used herein, vitamin E may be or may include α-tocopherol, γ-tocopherol, β-tocopherol, δ-tocopherol, α-tocotrienol, γ-tocotrienol, β-tocotrienol, δ-tocotrienol or one or more of any combination thereof. In at least one embodiment, vitamin E includes at least one of the four tocopherols. It should be understood that vitamin E and / or its isomers can be or can include natural forms of vitamin E, synthetic forms of vitamin E, or combinations thereof. Any one or more isomers of vitamin E can be "d" type, "l" type, or combinations thereof. In some embodiments, vitamin E is vitamin E acetate or vitamin E succinate. In some embodiments, vitamin E is vitamin E acetate.

[0179] As used herein, "vitamin C" can be ascorbic acid or a derivative thereof. Ascorbic acid exists as two enantiomers, usually denoted "l" ("levorotatory") and "d" ("dextrorotatory"). The "l" isomer is the most commonly encountered one. Ascorbic acid is also known as L(+)-ascorbic acid or l-ascorbic acid. The ascorbic acid derivative may be or may include, but is not limited to, L-ascorbic acid, calcium ascorbate, calcium l-ascorbate dihydrate, magnesium ascorbate, potassium ascorbate, magnesium L-ascorbyl phosphate (also known as: magnesium ascorbyl phosphate or magnesium ascorbyl phosphate), L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate, (+) sodium L-ascorbate, dehydro-l-(+)-ascorbic acid dimer, sodium ascorbyl phosphate (also known as: sodium ascorbyl phosphate, sodium l-ascorbyl phosphate, 2-phospho-L-ascorbic acid trisodium salt, L- Ascorbic acid 2-phosphate trisodium salt or L-ascorbic acid-2-phosphate sodium), ascorbic acid-2-glucoside, ascorbyl dipalmitate, ascorbyl methylsilanol pectate, ascorbyl stearate, ascorbyl sulfate disodium, ascorbyl 6-palmitate, ascorbyl phosphate calcium, ascorbyl acetate, ascorbyl propionate, ascorbyl stearate, ascorbyl palmitate, ascorbyl dipalmitate, ascorbyl glucoside, ascorbic acid polypeptide, ethyl ascorbyl ether, ascorbyl ethylsilanol pectate, etc., or a combination thereof.

[0180] As used herein, "vitamin D" refers to a group of fat-soluble open-ring steroids that are responsible for increasing intestinal absorption of calcium, magnesium, and phosphate, as well as many other biological effects. The two main forms are vitamin D2 or ergocalciferol, and vitamin D3 or cholecalciferol. Vitamin D includes vitamin D1 (a mixture of molecular compounds of ergocalciferol and luminosterol), vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol), vitamin D4 (22-dihydroergocalciferol), and vitamin D5 (glutamate).

[0181] As used herein, "vitamin K" is a group of compounds with a common chemical structure of 2-methyl-1,4-naphthoquinone. Vitamin K plays a role in blood coagulation, bone metabolism, and regulating blood calcium levels. Vitamin K includes vitamin K1 (phylloquinone) and vitamin K2 (menadione). Vitamin K2 has an unsaturated isoprenyl side chain and is designated as MK-4 to MK-13 based on the length of their side chains.

[0182] Optional ingredients that may be included in the skin care compositions of the present invention include: solvents; water-soluble alcohols, such as C 2-8 Alcohols, including ethanol; glycols, including propylene glycol, dipropylene glycol, tripropylene glycol, and mixtures thereof; glycerides, including mono-, di-, and triglycerides; medium- to long-chain organic acids, alcohols, and esters; surfactants, including emulsifiers and dispersants; amino acids, including glycine; structurants, including thickeners and gelling agents, such as polymers, silicates, and silica; emollients; fragrances; and colorants, including dyes and pigments.

[0183] The skin care compositions of the present disclosure (e.g., any of Compositions 1.0 et seq.) may optionally contain an emollient in any desired amount to achieve the desired emollient effect. Emollients are known in the art and are used to impart a soothing effect to the skin. Non-volatile emollients are preferred. Classes of non-volatile emollients include non-silicone emollients and silicone emollients. Non-volatile non-silicone emollients include benzoic acid C 12-15The non-volatile silicone material may be a polyether siloxane, a polyalkylaryl siloxane, or a polyether siloxane copolymer. An exemplary non-volatile silicone material is phenyl trimethicone. Examples include, but are not limited to, PPG-14 butyl ether, PPG-3 myristyl ether, secondary alcohol ethoxylates, stearyl alcohol, stearic acid and its salts, glyceryl monoricinoleate, isobutyl palmitate, glyceryl monostearate, isocetyl stearate, sulfated tallow, oleyl alcohol, propylene glycol, isopropyl laurate, mink oil, sorbitan stearate, cetyl alcohol, hydrogenated castor oil, stearyl stearate, hydrogenated soy glycerides, isopropyl isostearate, hexyl laurate, dimethyl brazilate, decyl oleate, diisopropyl adipate, dibutyl sebacate, diisopropyl sebacate, 2-ethylhexyl palmitate, isononyl isononanoate, isodecyl isononanoate, isotridecyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl stearate, di-(2-ethylhexyl) adipate, di-(2-ethylhexyl) succinate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, octadecyl alcohol, butyl stearate, glyceryl monostearate, polyethylene glycol, oleic acid, triethylene glycol, lanolin, castor oil, sunflower oil, acetylated lanolin alcohol, acetylated lanolin, petrolatum, isopropyl lanolin, fatty acids, mineral oil, butyl myristate, isostearic acid, palmitic acid, PEG-23 oleyl ether, oleyl oleate, isopropyl linoleate, cetyl lactate, lauryl lactate, myristyl lactate, quaternized hydroxyalkyl, aminoglucosamine esters, vegetable oil, isodecyl oleate, isostearyl neopentanoate, myristyl myristate, ethoxylated myristate oleyl, diethylene glycol stearate, ethylene glycol monostearate, myristyl stearate, isopropyl lanolin, paraffin, glycyrrhizic acid, hydroxyethyl stearamide. In some embodiments, the composition comprises an oil selected from the group consisting of sunflower oil, olive oil, shea butter, jojoba oil, almond oil, grape seed oil, rosehip seed oil, mink oil, castor oil, soybean oil, mineral oil, and combinations thereof. In certain embodiments, the composition comprises sunflower oil.

[0184] The skin care compositions of the present disclosure (e.g., any of Composition 1.0 et seq.) may optionally include one or more humectants. Humectants can reduce evaporation and also help preserve by reducing water activity and can also impart a desired sweetness or flavor to the composition. Exemplary humectants may be or may include, but are not limited to, glycerol, propylene glycol, polyethylene glycol, sorbitol, xylitol, etc., or any mixture or combination thereof. In some embodiments, the humectant is selected from glycerol, sorbitol, and combinations thereof. In certain embodiments, the humectant is glycerol.

[0185] The skin care composition of the present disclosure (e.g., any one of composition 1.0 et seq.) may optionally include a thickener. Exemplary thickeners may be or may include, but are not limited to, colloidal silicon dioxide, fumed silicon dioxide, cross-linked polyvinyl pyrrolidone (PVP) polymers, cross-linked polyvinyl pyrrolidone (PVP), etc., or mixtures or combinations thereof. In some embodiments, the thickening system includes a cross-linked polyvinyl pyrrolidone (PVP) polymer. Exemplary thickeners may also be or may include, but are not limited to, carbomer (e.g., carboxyvinyl polymer), carrageenan (e.g., Irish moss, carrageenan, iota-carrageenan, etc.), high molecular weight polyethylene glycol, cellulose polymers, hydroxyethyl cellulose, carboxymethyl cellulose and its salts (e.g., sodium CMC), natural gums (e.g., karaya gum, xanthan gum, gum arabic, and tragacanth gum), colloidal magnesium aluminum silicate, etc., or mixtures or combinations thereof. In some embodiments, the thickener includes or is a gum, and the gum is optionally selected from xanthan gum, carrageenan, and combinations thereof.

[0186] The skin care compositions of the present disclosure (e.g., any of Compositions 1.0 et seq.) may optionally contain one or more gelling agents. Examples of gelling agents include, but are not limited to, waxes, esters of fatty acids and fatty alcohols, triglycerides, partially or fully hydrogenated soybean oil, partially or fully hydrogenated castor oil, other partially or fully hydrogenated vegetable oils, stearyl alcohol, or other cosmetically acceptable materials that are solid or semi-solid at room temperature and provide a consistency suitable for application to the skin.

[0187] The skin care compositions of the present disclosure (e.g., any of Composition 1.0 et seq.) may optionally include one or more antioxidants. For example, one or more antioxidants may be added to the composition to act as ingredient protectors and maintain the long-term stability of the composition. Examples of optional antioxidants include, but are not limited to, citric acid, butylated hydroxytoluene, pentaerythritol tetra-di-tert-butyl hydroxyhydrocinnamate.

[0188] The skin care compositions of the present disclosure (e.g., any of Compositions 1.0 et seq.) may optionally include polymeric materials for thickening, such as polyamides, cellulose derivatives (e.g., hydroxypropyl cellulose, hydroxypropyl methylcellulose, etc.), and natural or synthetic gums such as polyglycerol esters (including agar, agarose, pectin, or guar gum), or mixtures or combinations thereof. A class of noteworthy materials for thickening the water-insoluble phase includes derivatives of hydrolyzed starch or other polysaccharides, particularly including esterified dextrins, such as dextrin palmitate. Another class of polymers particularly directed to structuring the oil phase containing silicone oils includes polysiloxane elastomers. Suspending agents such as silica or clays such as bentonite, montmorillonite, or hectorite (including those available under the trademark Bentone) may also be employed to thicken the liquid compositions according to the present invention. The composition may be thickened with a non-polymeric organic gelling agent, including selected dibenzylidene sugar alcohols (e.g., dibenzylidene sorbitol).

[0189] The skin care compositions of the present disclosure (e.g., any of Compositions 1.0 et seq.) may optionally contain a fragrance. Any fragrance suitable for skin care applications may be incorporated into the skin care compositions of the present disclosure. Fragrances tend to be relatively volatile aromatic compounds that are able to enter the vapor phase at skin surface temperature.

[0190] The skin care compositions of the present disclosure (e.g., any of Compositions 1.0 et seq.) can be made using methods known in the art. Typically, the ingredients are combined and optionally heated where necessary to melt the components. The components are mixed. Desirably, volatile materials such as fragrance materials are incorporated into the composition in the later stages of the mixing cycle to prevent their volatilization. After mixing, the composition can be poured directly into a dispenser and the container capped to preserve the product until use.

[0191] Example

[0192] Example 1

[0193] Non-limiting example skin care compositions (Example Compositions A to D) were prepared according to aspects of the present disclosure. The formulations of Example Compositions A to D are provided in Table 1 below (weight % of active material unless otherwise indicated):

[0194] Table 1

[0195]

[0196] * Columns A, B and D: Unless otherwise stated, amounts are given in effective % by weight.

[0197] ** Column C: Amounts given in % by weight of raw material.

[0198] Example 2 - Combination of α-tocopherol, malthionein and sodium PCA

[0199] In vitro studies were performed in a human keratinocyte culture model. Keratinocytes were treated with exogenous 0.3 wt% hydrogen peroxide to induce reactive oxygen species (ROS) production. The hydrogen peroxide-treated cells were then treated with α-tocopherol, malthionein, and PCA sodium, as well as with a combination thereof. ROS detection kits and fluorescent microplate readers were used to assess changes in ROS production.

[0200] Sample preparation: Human keratinocytes were plated in 24-well plates.

[0201] Raw materials:

[0202] α-Tocopherol

[0203] Mythioneine

[0204] Sodium PCA

[0205] 30% H2O2 (hydrogen peroxide)

[0206] Cellular ROS / Superoxide Detection Kit (Abcam-ab139476)

[0207] Reagents:

[0208] Culture medium EpiLife (Life Technologies)

[0209] Human Keratinocyte Growth Supplement (Life Technologies)

[0210] Stock solution:

[0211] Dissolve 10 μL of α-tocopherol (100%) in 990 μL of DMSO

[0212] (100%) to prepare 1 wt% α-tocopherol.

[0213] · Dissolve 100 μL of α-tocopherol (100%) in 900 μL of DMSO

[0214] (100%) to prepare 0.1 wt% α-tocopherol.

[0215] • 1 wt% erthioneine (EGT) was prepared by dissolving 10 μL of EGT in 990 μL of deionized water respectively.

[0216] • Prepare 10 wt% sodium PCA (NaPCA) by dissolving 1 mL of Na PCA (50%) in 5 mL of deionized water.

[0217] • Prepare 1 wt% sodium PCA (NaPCA) by dissolving 1 mL of Na PCA (50%) in 9 mL of deionized water.

[0218] Prepare 3 wt% H2O2 by dissolving 100 μL of H2O2 (30%) in 900 μL of deionized water.

[0219] - Prepare 10 wt% DMSO by dissolving 100 μL DMSO (stock 100%) + 900 μL cell culture medium.

[0220] dilution:

[0221] α-Tocopherol: 1 wt% stock solution in DMSO, filter sterilized Dilution 20 μL of (0.1%) + 980 μL = 1000 μL / 1 mL of (0.001%) (2X) Dilution 30 μL of (1%) + 970 μL = 1000 μL / mL of (0.001%) (3X) Dilution 40 μL of (1%) + 960 μL = 1000 μL of (0.001%) (4X)

[0222] Methioneine: 1 wt% stock solution in dH2O, filter sterilized Dilution 20 μL of (1%) + 980 μL = 1000 μL / 1 mL of (0.01%) (2X) Dilution 30 μL of (1%) + 970 μL = 1000 μL / mL of (0.01%) (3X) Dilution 40 μL of (1%) + 960 μL = 1000 μL of (0.01%) (4X)

[0223] Sodium PCA: 1 wt% stock solution in dH2O, filter sterilized Dilution 20 μL of (1%) + 980 μL = 1000 μL / 1 mL of (0.01%) (2X) Dilution 30 μL of (1%) + 970 μL = 1000 μL / mL of (0.01%) (3X) Dilution 40 μL of (1%) + 960 μL = 1000 μL of (0.01%) (4X)

[0224] H2O2: 3 wt% stock solution in dH2O, filter sterilized Dilution 200 μL of (3%) + 800 μL = 1000 μL / 1 mL of (0.3%) (2X) Dilution 300 μL of (3%) + 700 μL = 1000 μL / mL of (0.01%) (3X) Dilution 400 μL of (3%) + 600 μL = 1000 μL of (0.01%) (4X)

[0225] DMSO: 10 wt % stock in cell culture medium

[0226] Dilute 10 μL (10% stock solution) + 990 μL of cell culture medium = 1000 μL / 1 mL of (0.1%) (1X)

[0227] Dilution 20 μL (10% stock solution) + 980 μL of culture medium = 1000 μL / 1 mL (2X) Table 2

[0228]

[0229] Cell culture treatment

[0230] - 500 μL of each treatment sample was applied directly to a 24-well plate and incubated for 30 minutes.

[0231] • Post-incubation: Wash wells with provided wash buffer (1X).

[0232] • Then, 250 μL of medium containing green fluorescent (GF) dye was added to each well (2.5 μL of GF dye / 250 μL of medium) and incubated for 60 minutes.

[0233] After incubation, read fluorescence at 490 / 525 on a microplate reader.

[0234] Tested products:

[0235] The test samples are listed in Table 3.

[0236] Table 3

[0237]

[0238] result:

[0239] 0.3 wt % H2O2 treatment resulted in a significant increase in ROS production by human-derived keratinocytes.

[0240] • Combined treatment of human keratinocyte cultures with 0.001 wt% α-tocopherol + 0.01 wt% EGT + 0.01% sodium PCA reduced ROS generation by more than 82% (relative to 0.3 wt% H2O2 treatment).

[0241] This reduction in ROS caused by combined treatment with α-tocopherol, EGT, and sodium PCA was unexpected and significantly greater than the reduction observed by single treatment with 0.001 wt % of any of the following: α-tocopherol (70.72% reduction), 0.01 wt % EGT (74.5% reduction), and 0.01 wt % sodium PCA (37.9%), respectively.

[0242] The experiment was performed in three replicates. The results are shown in Tables 4 and 5 below.

[0243] Table 4 - Significant reduction in ROS production in keratinocytes induced by antioxidant treatment (fold change (relative to untreated))

[0244]

[0245] Table 5 - Reduction of ROS production in keratinocytes induced by antioxidant treatment (relative to untreated)

[0246]

[0247] The results showed that the combination of α-tocopherol, ergothioneine (EGT) and sodium PCA showed a significant reduction in ROS production in human keratinocyte cultures. The combination showed an unexpected effect in reducing ROS production in keratinocytes (treated with 0.3% hydrogen peroxide) relative to each individual treatment.

[0248] Example 3 - Combination of α-tocopherol, melathione and nicotinamide

[0249] In vitro studies were performed in a human keratinocyte culture model. Keratinocytes were treated with exogenous 0.3 wt% hydrogen peroxide to induce ROS production. The hydrogen peroxide-treated cells were then treated with α-tocopherol, malthionein, and nicotinamide, respectively, and in combination. Changes in ROS production were then assessed using a ROS detection kit and a fluorescent microplate reader.

[0250] Sample preparation: Human keratinocytes were plated in 24-well plates.

[0251] Raw materials:

[0252] α-Tocopherol

[0253] Mythioneine

[0254] Niacinamide

[0255] 30% H2O2 (hydrogen peroxide)

[0256] Cellular ROS / Superoxide Detection Kit (Abcam-ab139476)

[0257] Reagents:

[0258] Culture medium EpiLife (Life Technologies)

[0259] Human Keratinocyte Growth Supplement (Life Technologies)

[0260] Stock solution:

[0261] • Prepare 1 wt% α-tocopherol by dissolving 10 μL of α-tocopherol (100%) in 990 μL of DMSO (100%).

[0262] • 1 wt% ergothioneine (EGT) and niacinamide were prepared by dissolution at 10 mg / ml followed by filter sterilization.

[0263] Prepare 3 wt% H2O2 by dissolving 100 μL of H2O2 (30%) in 900 μL of deionized water.

[0264] - Prepare 10% DMSO by dissolving 100 μL DMSO (stock 100%) + 900 μL cell culture medium.

[0265] dilution:

[0266] α-Tocopherol: 1 wt% stock solution in DMSO, filter sterilized Dilution 10 μL of (1%) + 990 μL = 1000 μL / 1 mL of (0.01%) (1X) Dilution 20 μL of (1%) + 980 μL = 1000 μL / 1 mL of (0.01%) (2X) Dilution 30 μL of (1%) + 970 μL = 1000 μL / mL of (0.01%) (3X)

[0267] Dilute 40 μL (1%) + 960 μL = 1000 μL (0.01%) (4X)

[0268] Methioneine: 1 wt% stock solution in distilled water (dH2O), filter sterilized Dilution 10 μL of (1%) + 990 μL = 1000 μL / 1 mL of (0.01%) (1X) Dilution 20 μL of (1%) + 980 μL = 1000 μL / 1 mL of (0.01%) (2X) Dilution 30 μL of (1%) + 970 μL = 1000 μL / mL of (0.01%) (3X) Dilution 40 μL of (1%) + 960 μL = 1000 μL of (0.01%) (4X)

[0269] Nicotinamide: 1 wt% stock solution in dH2O, filter sterilized Dilution 10 μL of (1%) + 990 μL = 1000 μL / 1 mL of (0.01%) (1X) Dilution 20 μL of (1%) + 980 μL = 1000 μL / 1 mL of (0.01%) (2X) Dilution 30 μL of (1%) + 970 μL = 1000 μL / mL of (0.01%) (3X) Dilution 40 μL of (1%) + 960 μL = 1000 μL of (0.01%) (4X)

[0270] H2O2: 3 wt% stock solution in dH2O, filter sterilized Dilution 10 μL of (1%) + 990 μL = 1000 μL / 1 mL of (0.03%) (1X) Dilution 200 μL of (3%) + 800 μL = 1000 μL / 1 mL of (0.3%) (2X) Dilution 300 μL of (3%) + 700 μL = 1000 μL / mL of (0.01%) (3X) Dilution 400 μL of (3%) + 600 μL = 1000 μL of (0.01%) (4X)

[0271] DMSO: 10 wt % stock in cell culture medium

[0272] Dilute 10 μL (10% stock solution) + 990 μL of cell culture medium = 1000 μL / 1 mL of (0.1%) (1X)

[0273] Dilute 20 μL (10% stock solution) + 980 μL of culture medium = 1000 μL / 1 mL (2X)

[0274]

[0275] Cell culture treatment

[0276] - 500 μL of each treatment sample was applied directly to a 24-well plate and incubated for 30 minutes.

[0277] • Post-incubation: Wash wells with provided wash buffer (1X).

[0278] • Then, 250 μL of medium containing green fluorescent (GF) dye was added to each well (2.5 μL of GF dye / 250 μL of medium) and incubated for 60 minutes.

[0279] After incubation, read fluorescence at 490 / 525 on a microplate reader.

[0280] Tested products:

[0281] The test samples are listed in Table 6.

[0282] Table 6

[0283]

[0284] result:

[0285] 0.3 wt % H2O2 treatment resulted in a significant increase in ROS production by human-derived keratinocytes.

[0286] The combined treatment of human keratinocyte cultures with 0.01 wt% α-tocopherol + 0.01% EGT + 0.01% niacinamide resulted in a greater than 36% reduction in ROS production (relative to 0.3 wt% H2O2 treatment).

[0287] • This ROS reduction caused by the combined treatment of the three compounds was significantly greater than the reduction observed by the individual treatments of 0.01 wt% α-tocopherol, 0.01 wt% EGT, and 0.01 wt% niacinamide, respectively.

[0288] The experiment was carried out in three replicates. The results are shown in Tables 7 and 8 below.

[0289] Table 7 - Significant reduction in ROS production in keratinocytes induced by antioxidant treatment (fold change (relative to untreated))

[0290]

[0291] Table 8 - Reduction of ROS production in keratinocytes induced by antioxidant treatment

[0292]

[0293] The results show that the combination of α-tocopherol, ergothioneine (EGT) and nicotinamide provides a significant reduction in ROS production in human keratinocyte cultures. The combination also showed an unexpected effect in reducing ROS production in keratinocytes (treated with 0.3 wt % hydrogen peroxide) relative to each individual treatment.

[0294] Example 4 - Comparison of different ratios of α-tocopherol, EGT, and niacinamide

[0295] In additional experiments, different weight ratios of α-tocopherol to EGT to nicotinamide (α-tocopherol:EGT:nicotinamide) were tested to determine the efficacy in reducing ROS production in human keratinocyte cultures. A weight ratio of α-tocopherol to EGT to nicotinamide (α-tocopherol:EGT:nicotinamide) of 1:1:3 showed unexpected enhancement in reducing ROS production in keratinocytes (treated with 0.3 wt % hydrogen peroxide) relative to other ratios of the same ingredient combination, including 1:1:1 (α-tocopherol:EGT:nicotinamide).

[0296] Solutions with different ratios of α-tocopherol:EGT:nicotinamide were tested in an in vitro study conducted in a human-derived keratinocyte culture model. Keratinocytes were treated with exogenous 0.3 wt% hydrogen peroxide to induce ROS production.

[0297] Stock solution:

[0298] Prepare 1 wt% α-tocopherol by dissolving 10 μL of α-tocopherol (100%) in 990 μL of DMSO (100%).

[0299] 1 wt% niacinamide was prepared by dissolving in deionized water at 10 mg / mL followed by filter sterilization.

[0300] 1 wt% erthioneine was prepared by dissolving 10 μL of BioYouth EGT in 990 μL of deionized water followed by filter sterilization.

[0301] Prepare 3 wt % H 2 O 2 by dissolving 100 μL of H 2 O 2 (30%) in 900 μL of deionized water.

[0302] Prepare 10 wt% DMSO by dissolving 100 μL DMSO (stock 100%) + 900 μL cell culture medium.

[0303] dilution

[0304] α-Tocopherol: 1 wt % stock solution in DMSO, filter sterilized.

[0305] Dilute 10 μL of (1%) + 990 μL = 1000 μL / mL of (0.01%).

[0306] Nicotinamide: 1 wt % stock solution in distilled water (dH2O), filter sterilized.

[0307] Dilute 10 μL of (1%) + 990 μL = 1000 μL / mL of (0.01%).

[0308] Methioneine: 1 wt% stock solution in dH2O, filter sterilized.

[0309] Dilute 10 μL of (1%) + 990 μL = 1000 μL / mL of (0.01%).

[0310] H2O2: 3 wt% stock solution in dH2O, filter sterilized.

[0311] Dilution 100 μL of (3%) + 900 μL = 1000 μL / 1 mL of (0.3%). Evaluation plate layouts with components in different ratios are shown in Table 9 below.

[0312] Table 9

[0313]

[0314] Table 10 - Reduction of ROS production in keratinocytes induced by antioxidant treatment

[0315] deal with Fold change (relative to untreated) Unprocessed 1 <![CDATA[0.3% H2O2 in the untreated culture medium]]> 2.3 times increase 1:1:1 (α-tocopherol: EGT: niacinamide) 1.4 times reduction 2:1:1 (α-tocopherol: EGT: niacinamide) 1.4 times reduction 1:2:1 (α-tocopherol: EGT: niacinamide) 1.45 times reduction 1:1:2 (α-tocopherol: EGT: niacinamide) 1.47 times reduction 1:3:1 (α-tocopherol: EGT: niacinamide) 1.46 times reduction 3:1:1 (α-tocopherol: EGT: niacinamide) 1.39 times reduction 1:1:3 (α-tocopherol: EGT: niacinamide) 1.57 times reduction

[0316] Example 5 - Combination of α-tocopherol, melathione and niacinamide and UV protection

[0317] Exposure to UV radiation may result in increased photodamage in the form of thymine dimers. For example, due to exposure to UV radiation, adjacent thymine residues may become covalently linked, resulting in dimers. These dimers can be replicated as single bases, resulting in mutations. In addition, exposure to UV radiation may reduce enzymes such as catalase. Catalase is thought to convert reactive oxygen species such as hydrogen peroxide into water and oxygen, thereby reducing their toxic effects. In addition, exposure to UV is thought to reduce skin barrier proteins (such as loricrin) and extracellular matrix proteins (such as collagen).

[0318] The outermost layer (epidermis of the skin) functions to form a protective barrier against external environmental stress, chemical insults, and bacterial infection. The skin barrier contains many proteins, including loricrin. Loricrin is the major protein present in the terminally differentiated cornified envelope and contributes to the protective barrier function of the stratum corneum.

[0319] The extracellular matrix (ECM) is composed of many different macromolecules, including collagen, elastin, fibronectin, and laminin, all of which are thought to be organized in a tissue-specific manner. These protein components link together to form a structurally stable tissue support structure.

[0320] In these examples, Genoskin human skin explants were 1) left untreated; 2) exposed to 20 J / cm 2 1) UV (A+B); 2) placebo treatment followed by UV exposure; or 3) treatment with a mixture of α-tocopherol, ergothioneine (EGT) and nicotinamide in a weight ratio of 1:1:3, followed by UV exposure. For each treatment, changes in the number of thymine dimer-positive cells / field of view, the amount of catalase expression, and the fold changes in the expression of loricrin and the extracellular matrix protein collagen were measured.

[0321] According to the data, a combined mixture of alpha-tocopherol, ergothioneine (EGT) and niacinamide in a weight ratio of 1:1:3 is believed to be beneficial to the skin by reducing mutations that cause skin cell changes, restoring protective enzymes in the skin, and aiding barrier and extracellular matrix formation that mimics that of untreated / new skin.

[0322] method:

[0323] Tissue processing:

[0324] In vitro studies were performed using Genoskin human skin explants. Skin explants were first standardized with 1 mL of culture medium at least one hour before treatment and incubated at 37°C and 5% CO2, then untreated, treated with a placebo, or treated with a mixture of α-tocopherol, EGT, and nicotinamide in a weight ratio of 1:1:3 for α-tocopherol to EGT to nicotinamide. Skin explants treated with a placebo or a mixture of α-tocopherol, EGT, and nicotinamide received an application of a placebo or a mixture of α-tocopherol, EGT, and nicotinamide once a day for 5 days. On the sixth day, the treated skin explants were then exposed to UVA+UVB at 20 J / cm2. After UV exposure, tissue samples were then treated with a placebo or the mixture and incubated at 37°C and 5% CO2 for 24 hours. Tissue samples were then collected for RNA extraction and analysis or fixed with 4 wt% PFA followed by paraffin embedding.

[0325] Immunofluorescence staining:

[0326] The PFA-fixed and paraffin-embedded tissues were dewaxed by heat and xylene treatment, followed by hydration of the tissues by an ethanol gradient ranging from 100% to 50%, followed by hydration of the tissues by water. The tissue slides were then subjected to an antigen retrieval step for 30 minutes using a citric acid-based solution (pH 6.0), during which the tissue slides were immersed in the solution and heated using a commercially available hot plate stirrer. The tissue slides were then cooled to a temperature of 60°C and washed with 1X PBS. Subsequently, the tissue samples were blocked at room temperature in PBS containing 5% by weight goat serum and 0.1% by weight triton x100 for 1 hour and 30 minutes.

[0327] The primary antibody (anti-rabbit catalase) incubation was carried out overnight at a temperature of 4°C. After the primary antibody treatment, the tissue slides were washed in PBS and incubated with fluorescently labeled secondary antibodies (Alexa Fluor 488 dye, ThermoFisherScientific, A11006, 1:1000) at room temperature for 1 hour and 30 minutes. After the secondary antibody treatment, the slides were washed with PBS, then air-dried, and sealed with Prolong Gold antifade medium (vectashield antifade sealing medium with DAPI) (vector laboratories, H1200) containing DAPI nuclear counterstain. Images were collected by microscope EVOSFL Auto (Life technologies).

[0328] Immunohistochemistry and thymine dimers

[0329] The tissue sections were heated at a temperature of 60°C for 1 hour and then hydrated with xylene, 100% to 30% ethanol and deionized water. The tissue slides were then subjected to an antigen retrieval step for 30 minutes using a citric acid-based solution (pH 6.0), during which the tissue slides were immersed in the solution and heated using a commercially available hot plate stirrer. The tissue slides were then cooled to 60°C and washed with 1X PBS. Subsequently, the tissue samples were blocked at room temperature in PBS containing 5% by weight goat serum and 0.1% by weight triton x100 for 1 hour and 30 minutes. For DNA denaturation: the tissue sections were placed in 2N HCl at a temperature of 37°C for 30 minutes, followed by washing and hydrogen peroxide blocking at RT: 3% by weight hydrogen peroxide (1mL 30% hydrogen peroxide + 9mL PBS) for 15 minutes. The primary antibody was then applied and incubated at room temperature for 1 hour (thymine dimer (mouse monoclonal I1192-1.5μl in 1.5mL) 1:1000). This was followed by secondary antibody treatment with biotinylated Universal Antibody for 30 minutes at room temperature. RTUVectastain Elite ABC reagent was then applied at room temperature for 30 minutes, followed by ImmPACT NovaRED (5 mL diluent, 3 drops #1, 2 drops #2, 2 drops #3, 2 drops #4) and incubated for 2 minutes to 15 minutes. Finally, the tissues were counterstained with hematoxylin and mounted.

[0330] RT-QPCR:

[0331] RNA was extracted from RNAlater stabilized tissue using a homogenizer (Kinematica, Bohemia, NY) and the RNeasy Plus Mini kit (Qiagen) according to the manufacturer's protocol. The extracted RNA was quantified using NanoDrop One (ThermoFisherScientific). Based on RNA concentration, cDNA synthesis was performed using RT-qPCR with the Maxima First Strand cDNA Synthesis Kit with dsDNase (ThermoFisher) and Taqman TMArray cards were used for gene expression analysis using QuantStudio7Flex (ThermoFisher). 48 skin-specific targets and endogenous controls were selected for analysis. Relative quantification from treatments was calculated and compared to UV-only samples or untreated samples. Statistical significance was assessed using t-tests, and p-values ​​were corrected by the Benjamini-Hochberg false discovery rate using the Thermo Fisher Cloud application.

[0332] Reagents:

[0333] RNeasy Mini Kit (QIAGEN)

[0334] Thermo Scientific Maxima H Minus First Strand cDNA Synthesis Kit

[0335] TaqMan TM Fast Advanced Master Mix

[0336] result:

[0337] The tissues were left untreated, treated with UV only, treated with a placebo followed by UV, or treated with an antioxidant mixture of α-tocopherol, EGT, and nicotinamide in a weight ratio of α-tocopherol to EGT to nicotinamide of 1:1:3 followed by UV. After one week of treatment, the tissues were fixed and sectioned and immunohistochemically labeled with an antibody against thymine dimers.

[0338] The results showed that with UV light treatment, there was a significant increase in thymine dimer positive cells in the tissue. However, treatment with the antioxidant mixture showed a significant reduction in the effects of UV on the tissue. The data are shown in Tables 11 and Figure 1 middle.

[0339] Table 11

[0340]

[0341] *p<0.001 relative to “untreated”

[0342] **p<0.001 relative to "untreated + UV light"

[0343] ***Based on raw material weight.

[0344] The tissues were left untreated, treated with UV alone, treated with a placebo followed by UV light, or treated with an antioxidant cocktail followed by UV light. After one week of treatment, the tissues were collected and their RNA was extracted followed by cDNA synthesis. Quantitative real-time PCR (qRT-PCR) was performed to assess changes in gene expression of extracellular matrix proteins such as collagen (Col1A and Col3A) and skin barrier protein (loricrin). A summary of the results is presented in Tables 12, 13, and 14 and Figure 2A , Figure 2B and Figure 3 middle.

[0345] Table 12: Collagen 1A expression

[0346] deal with Fold change (relative to untreated) Unprocessed 1 Untreated + UV light 0.688 Placebo 1.985 α-Tocopherol + EGT + Nicotinamide (1:1:3)* 2.635

[0347] Table 13: Collagen 3A expression

[0348] deal with Fold change (relative to untreated) Unprocessed 1 Untreated + UV light 0.729 Placebo 1.428 α-Tocopherol + EGT + Nicotinamide (1:1:3)* 2.52

[0349] Table 14: Loricrin expression

[0350] deal with Fold change (relative to untreated) Unprocessed 1 Untreated + UV light 0.337 Placebo 0.412 α-Tocopherol + EGT + Nicotinamide (1:1:3)* 0.539

[0351] The tissue was not treated, only treated with UV, treated with placebo and then treated with UV light, or treated with an antioxidant mixture and then treated with UV light. After one week of treatment, the tissue was fixed and sliced, and immunohistochemically labeled with an antibody against catalase. For UV-treated tissue, catalase expression in the tissue was significantly reduced. However, the antioxidant mixture (alpha-tocopherol, EGT and nicotinamide) treatment provided a significant reduction in the effect of UV light on the tissue. The summary of the results from immunohistochemical labeling is described in Table 15.

[0352] Table 15: Immunofluorescence staining and catalase expression

[0353] deal with Mean gray intensity of catalase expression Unprocessed 14.7 Untreated + UV light 11.7 Placebo 10.6 α-Tocopherol + EGT + Nicotinamide (1:1:3)* 18.7

[0354] Example 5

[0355] Non-limiting example skin care compositions (Example Compositions E through H) were prepared according to aspects of the present disclosure. The formulations of Example Compositions E through H are shown in Table 16.

[0356] Table 16

[0357]

[0358] The present disclosure has been described with reference to exemplary embodiments. Although a limited number of embodiments are shown and described, it will be appreciated by those skilled in the art that changes may be made to these embodiments without departing from the principles and spirit of the foregoing detailed description. The present disclosure is intended to be interpreted as including all such modifications and changes as long as they fall within the scope of the appended claims or their equivalents.

Claims

1. A skin care composition comprising vitamin E, a thiourea derivative of histidine, a vitamin B3 compound and optionally pyrrolidone carboxylic acid and / or a salt thereof.

2. The skin care composition according to claim 1, wherein the vitamin E is selected from the group consisting of α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, tocopherol acetate, tocopherol phosphate, natural extracts rich in vitamin E derivatives, and combinations thereof.

3. The skin care composition according to claim 1 or claim 2, wherein the vitamin E is α-tocopherol or a surface-acceptable salt thereof.

4. A skin care composition according to any preceding claim, wherein vitamin E is present in an amount from about 0.1% to about 5% by weight, optionally 0.2% to 2%, or 0.2% to 1.5%, or 0.2% to 1.25%, or 0.2% to 1%, or 0.2% to 0.9%, or 0.2% to 0.8%, or 0.2% to 0.7%, or 0.2% to 0.6%, or 0.2% to 0.5%, or 0.2% to 0.4%, or 0.2% to 0.3%, or about 2%, or about 1.5%, or about 1.25%, or about 1%, or about 0.9%, or about 0.8%, or about 0.7%, or about 0.6%, or about 0.5%, or about 0.4%, or about 0.3%, by weight of the composition.

5. A skin care composition according to any preceding claim, wherein the thiourea derivative of histidine is erthioneine.

6. A skin care composition according to any preceding claim, wherein the ergothioneine is present at about 0.001% to about 2% by weight, based on the weight of the composition, optionally 0.001% to 2%, or 0.001% to 1.5%, or 0.001% to 1.25%, or 0.001% to 1%, or 0.001% to 0.5%, or 0.001% to 0.1%, or 0.001% to 0.05%, or 0.001% To 0.01%, or 0.001% to 0.0075%, or 0.001% to 0.005%, or 0.001% to 0.0025%, or 0.001% to 0.002%, or 0.001% to 0.0015%, or about 0.0015%, or about 0.002%, or about 0.0025%, or about 0.005%, or about 0.0075%, or about 0.01%, or about 0.05%, or about 1% is present.

7. A skin care composition according to any preceding claim, wherein the formula of vitamin B3 comprises: wherein R is -CONH2, -COOH or -CH2OH; and derivatives and / or salts thereof.

8. A skin care composition according to any preceding claim, wherein the vitamin B3 compound is present at about 0.1% to about 5% by weight, by weight of the composition, optionally 0.2% to 4.75%, or 0.2% to 4.5%, or 0.2% to 4.25%, or 0.2% to 4%, or 0.2% to 3.75%, or 0.2% to 3.5%, or 0.2% to 3.25%, or 0.2% to 3%, or 0.2% to 2.75%, or 0.2% to 2.5%, or 0.2% to 2. .25%, or 0.2% to 2%, or 0.2% to 1.75%, or 0.2% to 1.5%, or 0.2% to 1.25%, or about 0.2% to 1%, or about 4.75%, or about 4.5%, or about 4.25%, or about 4%, or about 3.75%, or about 3.5%, or about 3.25%, or about 3%, or about 2.75%, or about 2.5%, or about 2.25%, or about 2%, or about 1.75%, or about 1.5%, or about 1.25%, or about 1%, or about 0.5%.

9. A skin care composition according to any preceding claim, wherein the vitamin B3 compound comprises niacinamide.

10. A skin care composition according to any preceding claim further comprising water.

11. The skin care composition of claim 10, wherein the amount of water is from about 25% to 75% by weight of the composition.

12. The skin care composition of any preceding claim, wherein the composition comprises one or more amino acids selected from the group consisting of arginine, lysine, serine, citrulline, ornithine, creatine, histidine, diaminobutyric acid, diaminopropionic acid, alanine, aminobutyric acid, asparagine, cysteine, cystine, glutamine, glycine, hydroxyproline, isoleucine, leucine, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, salts thereof, or combinations of two or more thereof.

13. The skin care composition of claim 12, wherein the composition comprises taurine, arginine and glycine.

14. A skin care composition according to claim 12 or claim 13, wherein the weight ratio of taurine to arginine to glycine (taurine:arginine:glycine) of the skin care composition is (about 1.5 to about 69):(0.5 to 40):(0.5 to 1.5), respectively.

15. A skin care composition according to any preceding claim, wherein the composition comprises an additional ingredient selected from the group consisting of carnosine, cica, hyaluronic acid and its salts, magnesium sulfate, sugar isomerates, ketocarotenoids, nicotinamide adenine dinucleotide, and combinations of two or more thereof.

16. A skin care composition according to any preceding claim, wherein one or more ingredients are encapsulated in a delivery vesicle.

17. The skin care composition according to any preceding claim, wherein the delivery vesicle comprises one or more ingredients selected from the group consisting of polyglyceryl-10 dilinoleate, polyglyceryl-10 dipalmitate, polyglyceryl-10 dioleate, caprylic / capric triglyceride, and combinations of two or more thereof.

18. A skin care composition according to any preceding claim further comprising hyaluronic acid.

19. The skin care composition of claim 18, wherein the hyaluronic acid is low molecular weight HA, and wherein the molecular weight is about 300 kDa or less.

20. A skin care composition according to any preceding claim, comprising: Taurine, arginine and glycine, wherein the weight ratio of the taurine to the arginine to the glycine of the skin care composition (taurine:arginine:glycine) is (1.5 to 69):(0.5 to 40):(0.5 to 1.5); Mythioneine; alpha-tocopherol; and Vitamin B3 / Niacinamide.

21. A skin care composition according to any preceding claim, comprising: Taurine, arginine and glycine, wherein the weight ratio of the taurine to the arginine to the glycine of the skin care composition (taurine:arginine:glycine) is (1.5 to 69):(0.5 to 40):(0.5 to 1.5); Mythioneine; alpha-tocopherol; and Pyrrolidonecarboxylic acid and / or its salt.

22. A skin care composition according to any preceding claim, comprising: Taurine, arginine and glycine, wherein the weight ratio of the taurine to the arginine to the glycine of the skin care composition (taurine:arginine:glycine) is (1.5 to 69):(0.5 to 40):(0.5 to 1.5); Ethioneine (EGT); α-Tocopherol; Pyrrolidonecarboxylic acid and / or its salt; and Vitamin B3 / Niacinamide.

23. A skin care composition according to any preceding claim, comprising: Mythioneine; alpha-tocopherol; and Pyrrolidonecarboxylic acid and / or its salt, The weight ratio of the α-tocopherol to the EGT to the pyrrolidone carboxylic acid and / or its salt of the skin care composition (α-tocopherol:EGT:sodium PCA:pyrrolidone carboxylic acid and / or its salt) is (0.5 to 2):(0.5 to 20):(0.5 to 20), optionally 1:1:1, 1:1:2, 1:10:10, or any range thereof.

24. A skin care composition according to any preceding claim, comprising: Mythioneine; alpha-tocopherol; and Niacinamide, wherein the weight ratio of the α-tocopherol to the EGT to the niacinamide of the skin care composition (α-tocopherol:EGT:niacinamide) is (0.5 to 2):(0.5 to 20):(0.5 to 20), optionally 1:1:1, 1:1:2, 1:1:3, 1:2:1, 1:3:1, 2:1:1, 3:1:1, or any range thereof.

25. A skin care composition according to any preceding claim, comprising: Mythioneine; alpha-tocopherol; and Pyrrolidonecarboxylic acid and / or its salt, wherein the weight ratio of the α-tocopherol to the EGT to the pyrrolidone carboxylic acid and / or its salt (α-tocopherol:EGT:pyrrolidone carboxylic acid and / or its salt) of the skin care composition is the following weight ratio: (50 to 250):(0.5 to 20):(50 to 250), optionally 50:1:50, 50:1:100, 50:1:150, 50:1:200, 50:1:250, 100:1:50, 100:1:100, 100:1:150, 100:1:200, 50:1:250, 100:1:50, 100:1:100, 100:1:150, 100:1:200 1:200, 250:1:250, 250:1:50, 250:1:100, 250:1:150, 250:1:200, 250:1:250, or any range thereof, wherein the weight ratio is based on the active material weight of the ingredient.

26. A skin care composition according to any preceding claim, comprising: Ethioneine (EGT); alpha-tocopherol; and Niacinamide, wherein the weight ratio of the α-tocopherol to the EGT to the niacinamide (α-tocopherol:EGT:niacinamide) of the skin care composition is the following weight ratio: (50 to 250):(0.5 to 20):(100 to 500), optionally 50:1:100, 50:1:150, 50:1:200, 50:1:250, 50:1:300, 50:1: 350, 50:1:400, 50:1:450, 50:1:500, 100:1:100, 100:1:150, 100:1:200, 100:1:250, 100:1:300, 100:1:350, 100:1:400, 100:1:450, 100:1:500, 150:1:100, 150:1:15 0, 150:1:200, 150:1:250, 150:1:300, 150:1:350, 150:1:400, 150:1:450, 150:1:500, 200:1:100, 200:1:150, 200:1:200, 200:1:250, 200:1:300, 200:1:350, 200:1:4 1 :500, 250:1 :100, 250:1 :150, 250:1 :200, 250:1 :250, 250:1 :300, 250:1 :350, 250:1 :400, 250:1 :450, 250:1 :500, or any range thereof, wherein the weight ratio is based on the active material weight of the ingredient.

27. A skin care composition according to any preceding claim, comprising: Mythioneine; α-Tocopherol; Niacinamide; and Sodium PCA.

28. A skin care composition according to any preceding claim, wherein the skin care composition comprises: niacinamide in an amount from about 0.5% to about 5% by weight of the composition; From about 0.1% to about 2% by weight, based on the weight of the composition, of alpha-tocopherol; and About 0.001 wt % to 0.005 wt % erethione (EGT) based on the weight of the composition.

29. A skin care composition according to any preceding claim, wherein the skin care composition further comprises: 0.5% to 5% by weight of the composition of ascorbyl glucoside; and 0.001% to 0.05% astaxanthin by weight of the composition.

30. A skin care composition according to any preceding claim, wherein the skin care composition is delivered by transdermal injection.

31. The skin care composition of any preceding claim, wherein one or more ingredients are encapsulated in a delivery vesicle, and wherein from about 0.1 wt. % to about 15 wt. % of the ingredient is encapsulated in the delivery vesicle, based on the total weight of the skin care composition.

32. The skin care composition of claim 31, wherein niacinamide, carnosine, alpha-tocopherol, taurine, arginine, and glycine are each encapsulated in a delivery vesicle comprising MLVs.

33. The skin care composition of claim 32, wherein the weight ratio of the total amount of taurine, arginine and glycine to the amount of niacinamide to the amount of carnosine to the amount of alpha-tocopherol is about 2:1:1:1 or 2:2:1:1, respectively.

34. A skin care composition according to any preceding claim, wherein the skin care composition is in a form selected from the group consisting of serums, creams, moisturizers, masks, cleansers, oils, salves, lotions, gels, ointments, pastes, facial make-up and balms.

35. Use of a skin care composition according to any preceding claim for: activating skin cells of a subject in need thereof by applying an effective amount of the skin care composition to the skin; enhancing cellular energy in skin cells of a subject in need thereof; reducing or inhibiting cell damage in a subject in need thereof; and / or performing cellular detoxification in a subject in need thereof.

36. Use of a skin care composition according to any preceding claim for reducing redness and / or reducing skin pore size; reducing fine lines, wrinkles or scars; increasing skin smoothness, hydration and / or elasticity; reducing and / or inhibiting cellular damage in a subject in need thereof; detoxifying cells in a subject in need thereof by applying an effective amount of the skin care composition to the skin.

37. A skin care composition comprising: from about 0.1% to about 3% by weight of vitamin E, the vitamin E comprising tocopherol; from about 0.1% to about 7% by weight of an amino acid component comprising erthioneine; and about 0.7% to about 5% by weight of vitamin B, the vitamin B comprising niacinamide, All weight percentages are based on the total weight of the skin care composition.

38. The skin care composition of claim 37, wherein the skin care composition has a weight ratio of alpha-tocopherol to erthioneine of from about 6:1 to about 1:

6.

39. A skin care composition according to claim 37 or claim 38, wherein the skin care composition has a weight ratio of alpha-tocopherol to niacinamide of from about 1:1 to about 1:

11.

40. The skin care composition of any one of claims 37 to 39, wherein the skin care composition has a weight ratio of erthione to niacinamide of from about 1:1 to about 1:

11.

41. A skin care composition according to any one of claims 37 to 40, wherein the amino acid component further comprises taurine, arginine and glycine.

42. The skin care composition of claim 41, wherein the skin care composition has a weight ratio of the taurine to the arginine to the glycine (taurine:arginine:glycine) of from about 85:45:1 to about 45:24:

1.

43. The skin care composition of any one of claims 37 to 42, further comprising carnosine in an amount of about 0.1 wt.% to 5 wt.%.

44. A skin care composition comprising: from about 0.1% to about 3% by weight of vitamin E, the vitamin E comprising tocopherol; From about 0.1 wt % to about 7 wt % of pyrrolidone carboxylic acid and / or a salt thereof; and about 0.7% to about 5% by weight of vitamin B, the vitamin B comprising niacinamide, All weight percentages are based on the total weight of the skin care composition.

45. The skin care composition of claim 44, wherein the weight ratio of alpha-tocopherol to pyrrolidone carboxylic acid and / or salt thereof of the skin care composition is from about 6:1 to about 1:

6.

46. ​​A skin care composition according to claim 44 or claim 45, wherein the weight ratio of pyrrolidone carboxylic acid and / or salt thereof to niacinamide of the skin care composition is from about 1:1 to about 1:

11.

47. The skin care composition of any one of claims 44 to 46, wherein the skin care composition has a weight ratio of alpha-tocopherol to erthioneine of from about 6:1 to about 1:

6.

48. The skin care composition of any one of claims 44 to 47, wherein the skin care composition has a weight ratio of alpha-tocopherol to niacinamide of from about 1:1 to about 1:

11.

49. The skin care composition of any one of claims 44 to 48, wherein the skin care composition has a weight ratio of erthione to niacinamide of from about 1:1 to about 1:

11.

50. The skin care composition of any one of claims 44 to 49, further comprising carnosine in an amount of about 0.1 wt.% to 5 wt.%.

51. A skin care composition according to any one of claims 44 to 50, further comprising: From about 0.1 wt. % to about 7 wt. % of an amino acid component comprising erthioneine.

52. The skin care composition of claim 51, wherein the amino acid component further comprises taurine, arginine, and glycine.

53. The skin care composition of claim 52, wherein the skin care composition has a weight ratio of the taurine to the arginine to the glycine (taurine:arginine:glycine) of from about 85:45:1 to about 45:24:1.

Citation Information

Patent Citations

  • Component for external use

    CN102793632A

  • Antioxidant composition, antioxidant cosmetic composition and preparation method thereof

    CN113648236A

  • Cosmetic and dermatological compositions for dry skin

    EP1994923A2

  • Hair care compositions with selected amino acids and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines

    US20150164766A1

  • Cosmetic compositions containing vitamin b3

    WO2001000162A1